Yvonne H.C. Yau, MSc, Sarah W. Yip, MSc, PhD, and Marc N. Potenza, MD, PhD
CHAPTER OUTLINE
■ IMPULSE CONTROL DISORDERS: “BEHAVIORAL ADDICTIONS”?
■ PATHOLOGIC GAMBLING
■ BINGE EATING DISORDER
■ COMPULSIVE SEXUAL BEHAVIOR
■ PROBLEMATIC INTERNET USE
■ PROBLEMATIC VIDEO GAME PLAYING
■ COMPULSIVE BUYING DISORDER
■ KLEPTOMANIA
■ TRICHOTILLOMANIA
■ PATHOLOGIC SKIN PICKING
■ INTERMITTENT EXPLOSIVE DISORDER
■ CONCLUSION
The term “addiction” is derived from the Latin word addicere, meaning “bound to” or “enslaved by” (1). In its original formulation, the word was not linked to substance-use behaviors. As of several hundred years ago, the word became associated first with excessive alcohol and then with excessive drug use (2). By the time of the 1980s, the word was almost exclusively linked to excessive patterns of substance use, with experts involved in generating diagnostic criteria for drug dependence showing good agreement that the term applied to the condition of compulsive drug taking (3–5). However, by the early part of the 2000s, a growing movement to consider nondrug behaviors, such as gambling, sex, and eating (although by strict definition this last category does involve a substance—food), as addictive in nature was emerging (6). Aided by data from neurobiologic studies, this view is gaining momentum, leading to the consideration of a renaming of the “Substance-Related Disorders” diagnostic category to “Substance Use and Addictive Disorders” in the DSM-5 (1,7–11). Currently, only pathologic gambling (PG) has been proposed for inclusion in this category by the American Psychiatric Association (7). Other nondrug behaviors including problematic Internet use (PIU) and compulsive sexual behavior (CSB) (or hypersexual disorder) are proposed for inclusion in Section III, a section of the DSM-5 in which conditions that require further research will be included (12).
Addictions have been proposed to have several defining components: (a) continued engagement in a behavior despite adverse consequences; (b) diminished self-control over engagement in the behavior; (c) compulsive engagement in the behavior; and (d) an appetitive urge or craving state prior to the engagement in the behavior (1,13,14). If these elements are considered the core features of addictions, then excessive patterns of gambling and engagement in other non–substance-related motivated behaviors might be considered addictions. Consistently, the term “behavioral addictions” has been used recently to describe these disorders. Particularly relevant to addictions are aspects of motivation, reward processing, and decision making (15–17), and these features represent potential endophenotypes, or underlying constructs that may be more closely linked to biologic processes than are diagnoses, per se, that could be pursued in biologic investigations across a spectrum of substance- and non–substance-related addictive disorders.
Many disorders termed “behavioral addictions” are currently categorized as impulse control disorders (ICDs). The goals of this chapter are to review similarities between ICDs and substance-use disorders (SUDs) and discuss the implications for treatment and theory. First, the category of ICDs in the DSM-IV-TR is reviewed. Evidence from neurobiologic research, clinical reports, and pharmacotherapy studies regarding ICDs and their relationships with SUDs is reviewed. In reviewing the individual ICDs, consideration is initially given to disorders for which there have been arguably the most data supporting similarities with SUDs (e.g., in the areas of gambling and eating), with later portions focusing on ICDs for which there are arguably less data to support a categorization as a “behavioral addiction” (e.g., pathologic skin picking [PSP]).
IMPULSE CONTROL DISORDERS: “BEHAVIORAL ADDICTIONS”?
Many disorders that might be considered behavioral addictions are currently categorized in the Diagnostic and Statistical Manual as “Impulse Control Disorders Not Elsewhere Classified” (18). This title indicates that other disorders characterized by impaired impulse control, such as SUDs, attention deficit hyperactivity disorder (ADHD), bipolar disorder, cluster B personality disorders (i.e., antisocial, borderline, histrionic, narcissistic), among others, are categorized elsewhere in the manual. The ICDs within the “not elsewhere categorized” section include intermittent explosive disorder (IED), kleptomania, PG, pyromania, trichotillomania, and ICD not otherwise specified (NOS). Additional ICDs currently under consideration for DSM-5 include ones related to excessive Internet use, video game playing, buying or shopping, sex, and skin picking or nail biting (19). In addition, research criteria for binge-eating disorder (BED) are currently in the manual (20), and a case for inclusion of obesity has been forwarded (8), albeit debated (20a,20b). As discussed above, among issues being considered within research workgroups are whether the ICDs might be best categorized separately, with SUDs as addictions, or with obsessive–compulsive disorder (OCD) as obsessive–compulsive spectrum disorders (OCSDs) (8,10,19,21,22). Although the conceptualizations of ICDs as addictions or OCSDs are not mutually exclusive and data exist to support each formulation, these frameworks have important clinical implications with respect to prevention and treatment strategies (23–25). In the following sections, we review the ICDs, their main clinical features, and what is currently known regarding their biologies. A particular emphasis is placed on PG as it is arguably the best studied of the ICDs to date. However, for a more detailed description of the clinical features of PG and its treatment, we direct you to the chapter entitled, Pathologic Gambling: Clinical Characteristics and Treatment (26).
PATHOLOGIC GAMBLING
PG has been considered a chronic, lifelong condition, although more recent data are challenging this notion (1,24,27). PG and SUDs share clinical characteristics and diagnostic criteria. Individuals with PG often experience withdrawal, craving, tolerance, and failed attempts to reduce or abate gambling behaviors—all common features of SUDs. The DSM-IV diagnostic criteria for PG reflect these similarities. A diagnosis of PG requires that the patient display five or more of the following: preoccupation with gambling; gambling with greater amounts of money to receive the same level of desired experience (tolerance); repeated, unsuccessful attempts to reduce or quit gambling; is restless/irritable when trying to stop gambling (withdrawal); gambles to escape from a dysphoric state; gambles to regain gambling-related losses (“chases” losses); lies in significant relationships about gambling; engages in illegal activity in order to fund gambling; has risked/lost a job or significant other due to gambling; and relies on others to fund gambling. Additionally, an exclusionary criterion exists to specify that the gambling is not better accounted for by manic episodes.
A Nonsubstance Addiction?
SUDs and PG share phenomenologic features. As with SUDs, PG often begins in adolescence and young adulthood, and prevalence estimates of PG tend to decrease across the life span (28). A common feature of SUDs and PG is “telescoping”—the phenomenon whereby the time between initiation and problematic engagement in the addictive behavior is shorter in females than in males (28). These commonalities suggest that there may be shared developmental vulnerabilities for both disorders. In particular, the high prevalence estimates in adolescents (29) suggest common vulnerability factors (e.g., impaired impulse control) for both SUDs and PG. There additionally exist high comorbidity rates for PG and SUDs, with co-occurrence estimates as high as 39.0% for comorbid substance abuse in clinical populations (30) and elevated odds (as high as 76.3%) observed in community samples as well (31,32).
Neurocognition
Neurocognitive measures provide insight into neurobiologic functioning. For example, neurocognitive research suggests a dysregulation of the ventromedial prefrontal cortex (vmPFC) and orbitofrontal cortex (OFC) in individuals with PG (33,34). Individuals with PG display impaired performance on the Iowa gambling task (IGT), a task involving risk/reward decision making (35,36). Other populations with impaired performance on the IGT include individuals with SUDs, schizophrenia, or vmPFC lesions. Goudriaan et al. (37) reported that individuals with PG and individuals with a history of alcohol dependence both had impaired performance on neurocognitive tasks involving inhibition, time estimation, cognitive estimation, and planning tasks in comparison to normal controls and to individuals with Tourette syndrome, who only had an impaired performance on inhibition tasks. Neurocognitive measures of disinhibition and decision making are also positively associated with problem-gambling severity (38) and may predict the relapse of PG (39). Both individuals with problem gambling and those with alcohol dependence display alterations in risky decision making and reflection impulsivity—processes involving the vmPFC—in comparison to matched controls (40). These data highlight some of the clinical similarities between PG and SUDs and suggest similarities in underlying neurobiologic deficits. As such, neurocognitive research may be a useful tool in the identification of brain regions of interest warranting further investigation via more direct imaging-based modalities.
Delay Discounting
Individuals with PG often make disadvantageous decisions, selecting small immediate rewards over larger delayed rewards (e.g., “I’ll go gambling one last time.”). This rapid temporal discounting of rewards has been termed delay discounting, as rewards are more steeply discounted as a function of delay duration (41). Poorer performance on delay discounting measures (i.e., discount rewards more rapidly) has been observed in multiple populations, including individuals with SUDs (42). A dose-dependent relationship has been found between level of alcohol use and patterns of delay discounting (42). A similar additive effect has also been reported among heroin users in relation to needle sharing: users who engaged in needle sharing scored more highly than did non– needle-sharing heroin users on delay-discounting measures (42). Together, these data suggest that multiple risk factors may contribute to rates of delay discounting. Individuals with comorbid SUDs and PG discount rewards more rapidly than do PG individuals without SUDs (41,43). It is unclear whether comorbid SUDs and PG promote delay discounting or whether delay discounting is a vulnerability factor for comorbidity.
Although some data exist to suggest that abstinent substance users perform better (display less delay discounting) than do current substance users on delay-discounting measures, other data suggest no significant differences (42). A recent study suggests that delayed discounting did not differ between PG individuals before treatment and 1 year after treatment (44). To our knowledge, this is the first study that investigates delayed discounting among abstinent PG individuals. Further research into the effect of abstinence on delay discounting is needed.
Delay discounting involves aspects of reward evaluation, and multiple brain regions contribute to reward processing in humans (45,46). Amongst the most widely implicated brain regions in subjective reward valuation is the nucleus accumbens (NAcc), situated in the ventral striatum (47–49). In healthy controls, the anticipation of working for or receiving monetary rewards is associated with ventral striatal activation, whereas an increase in vmPFC activation is associated with the processing of actual reward outcomes during performance of a monetary incentive delay task (50,51). An effective functional balance between these reciprocally connected neural regions may mediate appropriate and advantageous behavioral responses to varying reward contingencies. A recent functional magnetic resonance imaging (fMRI) study reported increased delay discounting among pathologic gamblers as well as an association between decreased activations in the ventral striatum and OFC and probability discounting compared to matched controls (46). Preclinical research suggests that diminished serotonin (5-HT) activity in the forebrain may hypersensitize animals to delays, influencing patterns of delay discounting (52). Further research is needed to determine the relationship among 5-HT regulation, prefrontal cortical activation, and delay-discounting behavior in humans.
Neurocircuitry
Corticostriatal and forebrain neuromodulatory systems have been implicated in delayed and probabilistic reward (i.e., delay discounting) (52). Research suggests that dysregulation of the mesocorticolimbic dopamine (MCL DA) system may contribute to PG. The MCL DA system, often referred to as the “reward pathway,” has long been implicated in SUDs (53,54). Given the phenomenologic (e.g., craving, tolerance) and neurocognitive (e.g., delay discounting) similarities between PG and SUDs, it is possible that these disorders may share similar neurobiologic abnormalities, and current investigations are examining this hypothesis.
There have been several fMRI studies of PG that suggest that specific brain regions contribute to the pathophysiology of PG. For example, Potenza et al. (55) have reported reduced frontal cortical, basal ganglia, and thalamic activations in response to gambling videos—during the period prior to the subjective onset of emotional or motivational response—among PG subjects (vs. controls). This finding differed from those observed in similar studies involving subjects with OCD in which relatively increased activation of these regions was observed in the patient group. In particular, when viewing the portion of the videotapes during which the most robust gambling stimuli (e.g., video clips of a gambling public service announcement involving slot machines or an advertisement for a casino in which table gambling is shown) were presented, individuals with PG displayed relatively less activation of the vmPFC. Diminished activations of the vmPFC among individuals with PG as compared to control subjects have also been observed in other studies across a range of fMRI tasks, for example, the Stroop color–word interference task (56), a monetary incentive delay task (57), and a simulated gambling task (53). Similarly, individuals with SUDs either with or without co-occurring PG show relatively diminished activation of the vmPFC during performance of the IGT (58), in comparison to control subjects. Together, these data indicate an important role for the vmPFC in PG.
Multiple studies also implicate the striatum in PG. For example, Reuter et al. (53) observed significantly less vmPFC and ventral striatal activation in PG participants compared to control subjects during a simulated gambling task. Both right ventral striatal activation and vmPFC activation were inversely correlated with severity of gambling symptomatology in PG subjects, indicating that the less the activation of these brain regions, the greater the gambling pathology. Other fMRI studies during gambling-cue exposure have similarly observed diminished activation in the ventral (33) and dorsal striatum (59) in PG participants (vs. controls). As dopamine (DA) is an important neurotransmitter for both vmPFC and ventral striatal functioning, these findings appear consistent with the hypothesis of a dysregulation of DA among individuals with PG (53). However, as these studies did not directly measure DA levels, further investigation into the relationship between DA and PG in relation to the reward pathways is needed to test this hypothesis.
Neurostructure
In recent years, multiple studies have investigated the neurostructural correlates of psychiatric disorders using either diffusion tensor imaging (DTI) or voxel-based morphometry (VBM) to assess white and gray matter structures, respectively. Findings from DTI studies indicate similar alterations in white matter microstructures encompassing regions of callosal, association, and projection fiber tracts between PG (60,61) and SUDs (62–65). Among individuals with PG, a history of previous alcohol abuse or dependence is associated with a greater magnitude of white matter micro-structural alterations within regions of the corpus callosum, and white matter integrity within the corpus genu is associated with increased levels of self-reported impulsivity (61). Together, these data provide preliminary evidence for white matter involvement in the pathophysiology of PG.
To our knowledge, there have been only two published VBM studies conducted among individuals with PG (66). In both studies, no significant differences were reported in gray matter volumes between individuals with and without PG. Van Holst et al. additionally reported significant increases in gray matter volumes among individuals with PG, in comparison to individuals with alcohol dependence. These data therefore do not support the general hypothesis of altered gray matter macrostructures in PG; however, future studies employing larger samples should examine further gray matter contributions to PG and explore the relationship between gray matter volumes and clinical variables among individuals with PG.
Neurochemistry
Serotonin (5-HT)
Serotonin neurons project from the raphe nucleus of the brain stem to multiple brain regions including the hippocampus, amygdala, and prefrontal cortex (PFC). It has been hypothesized that dysregulated 5-HT functioning may mediate behavioral inhibition and impulsivity in PG (34,67,68). Data from studies of cerebrospinal fluid (CSF), pharmacologic challenge studies, and preclinical investigations together suggest a role for 5-HT in PG.
Low CSF levels of the 5-HT metabolite 5-hydroxyin-doleacetic acid (5-HIAA) have been reported in individuals with PG (69). Low CSF levels of 5-HIAA in humans have been associated with violence, suicidality, and impulsive aggression (52) and observed in other psychiatric disorders including other ICDs and alcohol abuse/dependence. Evidence from preclinical research has also identified a correlation between risk-taking behaviors and lowered CSF levels of 5-HIAA in monkeys (52) and rats (70). Low levels of platelet monoamine oxidase (MAO) activity, considered a peripheral marker of 5-HT activity, have been reported among males with PG (71,72). Consistent with findings of 5-HIAA CSF levels, lowered levels of platelet MAO have additionally been reported in both suicidal and risk-taking individuals (73).
5-HT receptor sensitivity has been investigated via the administration of the 5-HT1/5-HT2 receptor partial agonist meta-chlorophenylpiperazine (m-CPP). Individuals with PG, like those with SUDs, report a euphoric or “high” response to the m-CPP, whereas control subjects report an unpleasant response (74), along with an enhanced prolactin response (75). In PG, this differential response was associated with severity of PG symptomatology, with higher scores on the Yale-Brown Obsessive–Compulsive Scale Modified for PG, a PG severity rating scale, significantly correlating with increased prolactin responses. In response to the 5-HT1B/1D receptor agonist sumatriptan, a blunted growth hormone and prolactin response was observed among PG individuals (vs. controls), a response that suggests decreased 5-HT receptor sensitivity (76), similar to that observed among alcohol-dependent individuals (77). Furthermore, disturbances in 5-HT function, as reflected by blunted prolactin response to m-CPP, appear associated with severity of drug use among cocaine-dependent individuals (78). Taken together, these studies suggest that responses to 5-HT agonist administration are similar to those reported for substance-related addictions.
Other pharmacologic studies support the hypothesis that there is a dysregulation of the 5-HT system in PG. Among individuals with PG, 5-HT1B receptor availability within both the ventral striatum/pallidum and the anterior cingulate is positively correlated with problem-gambling severity (as assessed using the South Oaks Gambling Screen) (79). In some studies, selective serotonin reuptake inhibitors (SSRIs), such as fluvoxamine and paroxetine, have been found to improve social functioning and reduce gambling behaviors and thoughts about gambling in PG (80). However, clinical trial findings involving SSRIs have generally been negative or mixed (80–84). As such, the precise role for SSRIs in the treatment of PG remains an active area of investigation (68,85).
Dopamine
DA has been implicated in rewarding and reinforcing processes in drug addiction. There have been several recent ligand-based studies investigating DA functioning among individuals with PG versus healthy controls. For example, Linnet et al. (86) have reported in a very small sample a positive association between self-reported excitement levels during IGT performance and DA release within the ventral striatum among individuals with PG. Joutsa et al. (87) reported that whereas individuals with PG and healthy controls showed similar levels of DA release during slot-machine-task performance, DA release was positively correlated with problem-gambling severity among PG individuals. Similarly, there have been two recent reports of no alterations in overall DA receptor binding within the striatum among individuals with PG (88,89), despite significant correlations between D3 receptor binding and both problem-gambling severity and impulsivity within the dorsal striatum (88), as well as between mood-related impulsivity and D2/D3 receptor binding within the striatum (89) among individuals with PG. Taken together, these data suggest that the clinical presentation of PG may be partially mediated by DA (e.g., DA release is associated with gambling-related excitement and PG severity) but do not support the hypothesis of a general alteration in DA receptor availability among individuals with PG.
Psychopharmacologic data suggest that the DA system may influence impulsive behavior, although the precise manner is not completely understood. Stimulants such as amphetamine increase DA release and prevent DA uptake within the synaptic cleft and lead to improved impulse control in individuals with ADHD (52). However, amphetamine administration in PG has been associated with the priming of gambling motivations (90,91). Whereas DA agonists have been associated with PG and other ICDs in the treatment of Parkinson disease (PD) (92–94), the DA D2-like receptor antagonist haloperidol has been reported to enhance the rewarding and priming effects of gambling in PG (90), though individual differences also appear important (95). Investigations of CSF DA levels in PG have also yielded equivocal findings. Decreased CSF levels of DA and increased levels of the DA metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid have been reported in PG (96). However, these findings were no longer present when correcting for CSF flow rate (69). A more recent investigation reported increased levels of CSF HVA among individuals with PG (97). The authors additionally reported enhanced levels of 5-HIAA, a finding different from their earlier investigations of CSF 5-HT metabolite concentration levels (69). These data highlight the need for studies using larger carefully controlled samples, while accounting for mediating factors such as comorbid pathologies and CSF flow rate.
Norepinephrine and Arousal in PG
Dysregulation of norepinephrine (NE)—a neurotransmitter implicated in arousal-, attention-, and sensation-seeking behaviors—has been reported in individuals with PG. Individuals with PG have elevated urinary concentrations of NE, as well as elevated CSF levels of a metabolite of NE (metabolite 4-hydroxy-3-methoxyphenyl glycol) (98). Research supports dysregulated hypothalamic–pituitary–adrenal axis regulation in PG. Meyer et al. (99) measured the neuroendocrine responses to “real-life” casino gambling in problem gamblers and found that problem gamblers had higher heart rates and elevated NE and DA levels in comparison to controls. In a separate study, PG individuals (vs. controls) showed a higher growth hormone peak response to clonidine—an adrenergic agonist used to assess NE function—the magnitude of which was positively correlated with problem-gambling severity (100). Together, these data suggest that there may be an elevation of NE activity in PG that may be potentiated by gambling behaviors.
Opioids
Pharmacologic challenge studies suggest a dysregulation of the opioid system in PG. Naltrexone and nalmefene, both opioid receptor antagonists, have been found to reduce gambling-related thoughts and behaviors in individuals with PG (101–104). Kim et al. (101) conducted a double-blind study of naltrexone in a sample of 89 individuals with PG and found that naltrexone (vs. placebo) administration at a mean dosage of 188 mg/d reduced subjective craving reports. Consistent with previous research demonstrating naltrexone’s dose-dependent hepatotoxicity, approximately 20% of participants displayed liver function test abnormalities subsequent to naltrexone treatment (101,102). A randomized double-blind study of nalmefene, an opioid antagonist that has not been associated with hepatotoxicity, found significant improvement in PG symptoms subsequent to lose-dose (25 mg/d) treatment in comparison to controls (102); moreover, a post hoc study suggests that medication dosage appears to be important in achieving symptom control (104). Together, these data suggest an important role for opioid antagonists in the treatment of PG as there is in alcohol and opiate use disorders.
Population Genetics
Family- and twin-based studies of addiction indicate that genetic factors are important in the development of drug and alcohol abuse. Family studies of PG suggest a significant parental influence on the development of offspring gambling behaviors (105). Gene/environment data suggest that the cross-generation transmission of drug addiction involves both environmental and genetic factors. Data derived from the Vietnam Twin Era Registry found that between 35% and 54% of the probability of meeting criteria for a DSM-III-R diagnosis of PG were attributable to heritable factors (106). Data from the same sample reported that 34% of the probability of developing drug dependence was attributable to inherited factors, suggesting similar degrees of heritability for PG and SUDs (107). Another study using the same population found that PG and alcohol dependence shared genetic and environmental contributions (108). Shared genetic and environmental factors may not be limited to SUDs, with both contributing to externalizing conditions like conduct and antisocial personality disorders as well as internalizing conditions like anxiety disorders, although genetic factors may contribute more prominently to the co-occurrence of PG and internalizing disorders (109).
Emerging data suggest that genetic factors may contribute substantially to the development of disordered gambling (DG)—a term that refers to the full continuum of gambling-related problems, including PG. Slutske et al. (110) reported that 49% of the probability of developing DG can be attributed to genetic influences and argue that there was no evidence for shared environmental influences. Moreover, correlations between DG symptoms and lifetime major depression, cigarette smoking, and alcohol and nicotine dependence are largely genetically determined (83%) (111).
Genetic Polymorphisms in PG
Molecular genetic research has identified specific genetic alleles associated with PG. Genetic polymorphisms related to genes encoding for the DA-related moieties (DRD1Ddel, DRD2 Taq I A, DRD4 [exon III]) (112–116) have been implicated in PG, though negative results have also been observed (117). Variants of the serotonin transporter gene promoter region (5HTTLPR) (73) and MAOA enzymes (MAO-A [intron I], MAO-A [promoter], MAO-B [intron II]) (71,72) have been reported in association with PG. Similarities with respect to allelic distributions have been reported in PG and drug and alcohol dependence; for example, variations in DRD2 and MAOA genes have been linked to PG and alcohol abuse and dependence, and DRD4 variants have been linked to PG and alcohol, cocaine, and heroin abuse and dependence (118). These and other molecular genetic studies of PG should be considered preliminary in nature given relatively small samples, incomplete subject characterization, and frequent absence of stratification by race/ethnicity (119,120), particularly as some early results have not replicated in studies using alternate designs (e.g., discordant sibling pairs) (113).
Conclusion
Although PG was initially included in the DSM in 1980, the precise neurobiology of PG remains incompletely understood. However, growing evidence from neurocognitive, neurochemical, neuroimaging, and genetic research suggest that PG may share similar pathophysiologies with disorders involving poor impulse control, such as SUDs. There are important treatment implications inherent in these similarities. For example, the biologic similarities between SUDs and PG could help to guide treatment development.
BINGE EATING DISORDER
Although specific drugs of abuse have different influences on eating behaviors (e.g., weight loss with amphetamine and increased food intake with marijuana), data suggest that both substance-use and eating behaviors may be modulated by the same motivational neurocircuitry leading to the conceptualization of “foods as drugs” (121). The DSM-IV-TR category of eating disorders includes anorexia nervosa (AN), bulimia nervosa (BN), and eating disorder not otherwise specified. Although not specifically included in the main portion of the DSM-IV-TR, BED—distinct from BN as it does not include compensatory behaviors such as purging—is associated with obesity and other negative sequelae. The recent rise in the prevalence of obesity within the population has led to more research on obesity and related disorders like BED. Given that BED has an important element of episodic behavioral dyscontrol similar to the formal ICDs, this section focuses primarily on the neurobiology of this disorder. For a review of AN and BN, see Ref. (122). Preclinical data relevant to BED and obesity will also be described.
Epidemiology
Previously listed as an eating disorder NOS, BED is to have its own diagnostic code in the DSM-5 (123). The proposed diagnostic features are very similar to the diagnostic features of SUDs and ICDs: recurrent episodes, impaired control, and marked distress in relation to binge eating. The DSM-IV-TR also notes that individuals may make repeated unsuccessful attempts to stop binge eating and that they may report that their binge eating has detrimental social and occupational effects—two important criteria for substance dependence. Over a quarter of clinicians report often or always using addiction-based therapies for BED (124), further suggesting phenomenologic and clinical similarities between BED and SUDs.
Obesity, a common consequence of binge eating, is increasingly common. Defined as “abnormal or excessive fat accumulation that may impair health” (125), it is estimated that up to 35.7% of the U.S. population meets the criteria for obesity (126). Globally, estimates from 2008 suggest that 1.4 billion adults were overweight and that at least 200 million men and 300 million women were obese (125). Associated medical conditions include type II diabetes, stroke, osteoarthritis, heart disease, and cancer (125,127). Frequently co-occurring psychiatric disorders include depression, anxiety, personality disorders, and lifetime SUDs (128). Features of PG among individuals with BED are associated with decreased self-esteem and increased substance-use problems (129).
While there are strong links between BED and obesity (130), it is important to note that obesity and addiction are not necessarily related and that for some individuals, overeating is a relatively passive event that takes the form of liberal snacking and eating large portions (131). BED may be a specific subtype of obesity driven by a biologically based hyperreactivity to the hedonic properties of food, coupled with an enhanced motivation to encourage appetitive behaviors that is related to neurobiologic differences in reward and control circuitry (132–134).
Conceptualization and Treatment
Along with the recent rise in the prevalence of obesity, there has been a concurrent rise in the number and diversity of treatment interventions. Such interventions range from preventative interventions, such as the incorporation of nutrition classes into school curriculums, to pharmaceutical interventions, such as the administration of appetite-suppressing drugs and use of surgical innervations like gastric bypass surgery. Because some treatment interventions for obesity are highly invasive (e.g., gastric bypass, jaw wiring), it is important to examine and assess not only efficacy but also tolerability and impact on quality of life. It is also important to understand the pathophysiology underlying the disorder, particularly if individual differences contribute to selection of effective interventions.
The Biology of Eating Behaviors
The hypothalamus (via regulatory neuropeptides such as leptin, cholecystokinin (CCK), and ghrelin) is an important site for the maintenance of energy homeostasis. Lesions to the ventromedial hypothalamus result in hyperphagia and obesity, whereas lesions to the lateral hypothalamus (LH) result in hypophagia and weight loss. This finding led researchers to conceptualize the LH as a “feeding center” and the ventromedial nucleus as a “satiety center.” In this “dual-center” model of eating behavior, the hypothalamus plays a central role and hypothalamic function contributes significantly to homeostatic regulation within a larger motivational network (135).
Leptin
Leptin, an adipose-derived hormone, is a chemical modulator involved in the maintenance of energy homeostasis and feeding behaviors (136). Leptin is also implicated in other reward-seeking behaviors (136,137) including SUDs (138). Leptin acts as a peripheral metabolic cue within the central nervous system to modulate neuronal activity in brain areas involved in appetite control, including the hypothalamus. Administration of exogenous leptin increases energy expenditure and reduces hyperphagia and obesity in genetically leptin-deficient mice and humans (ob/ob) (139). However, leptin deficiency syndrome is extremely rare in humans (140). A recent fMRI study investigated three adults with genetically mediated leptin deficiency 5 and 6 years post– leptin replacement treatment. A longer duration of replacement treatment was associated with increased activation in a ventral portion of the posterior cerebellum in response to food images, whereas decreases in body mass were associated with decreased activation in this area (141). Another fMRI study similarly presented visual food and nonfood stimuli during a fasting state and a fed state, both before and after leptin treatment, to two adolescents. Results yielded significant behavioral and neural response changes between conditions. When participants rated their level of preference for specific foods presented, leptin administration was associated with decreased preference ratings during the fed condition. Whereas activation in the NAcc and caudate nucleus of the striatum was positively correlated with preference ratings in both the fed and fasting conditions prior to leptin treatment, subsequent to leptin treatment striatal activation was only positively associated with preference ratings in the fasting condition (142). These data demonstrate extrahypothalamic action of exogenous leptin and suggest that leptin may help to encode palatability.
Leptin and DA-Regulated Reward Processing
Mesolimbic reward pathways play an important role in eating behaviors. Increased activation of brain regions implicated in substance use and dependence—such as the OFC, insula, striatum, and midbrain—have been observed subsequent to the consumption of palatable food (143). Differential striatal activation in response to food has also been reported in obese individuals in comparison to healthy control subjects. An fMRI study of 13 obese females and 13 female controls found that obese (vs. control) females selectively activated the dorsal striatum in response to images of high-calorie foods (144). Moreover, in response to high-calorie food stimuli, body mass index (BMI) was predictive of dorsal striatum, anterior insula, claustrum, posterior cingulate, and postcentral and lateral OFC activation (144). A separate study found that obese versus lean individuals showed elevated corticostriatal responses to favorite-food cues, with thalamic activation mediating the relationship between insulin resistance and food craving in the obese but not in the lean individuals (145). Based on previous reports of lowered DA levels in AN (146), one study investigating potential striatal differences found that whereas healthy control subjects displayed differential ventral striatal activation for rewards versus losses in a monetary reward task, women who had recovered from anorexia showed no activation differences for wins and losses, suggesting a reduced experience of reward (147). A more recent study reported increased striatal activations to both pleasant and aversive food stimuli among women recovered from anorexia (vs. healthy controls), further suggesting that alterations in reward processing may be implicated in the pathophysiology of disordered eating behaviors (148).
Preclinical research using pharmacologic and genetic knockout strategies suggests that D2 receptor blockade attenuates the acute hypophagic effect of leptin in fasted mice (149). A reduced availability of DA D2 receptors in the striatum has been reported in individuals with SUDs (150,151) and in obese individuals, with receptor availability negatively correlated with BMI (152,153). Preclinical research has demonstrated that knockdown of striatal DA D2 receptors rapidly accelerates the development of addiction-like reward deficits and the onset of compulsive-like food seeking in rats (154). Together, these data suggest dys-regulated striatal function in eating disorders that at least in part reflects dysregulated DA function.
Whereas leptin-modulated hypothalamic activity has been well documented, research suggests that leptin acts directly on other brain regions, including the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) of the midbrain. DA neurons in the VTA and SNc project to the striatum and are implicated in reward, motivation, and addiction. Preclinical data (155) have demonstrated that DA neurons within the VTA express mRNA encoding for both leptin and insulin receptors. Exogenous leptin administration to the VTA results in a decrease in food consumption, and intravenous exogenous leptin administration reduces the firing of VTA DA neurons (156). The expression of mRNA encoding the long form of the leptin receptor (ObRb) has additionally been reported in regions including the hippocampus, brain stem, cortex, thalamus, cerebellum, and substantia nigra (157). Leptin has additionally been reported to enhance synaptic plasticity in brain regions such as the hippocampus (158).
Preclinical research using self-administration of electrical brain stimulation of reward (BSR) technology suggests that leptin influences drug-taking behaviors. An investigation by Fulton et al. (159) found increased BSR in response to fasting conditions, which was attenuated by direct exogenous leptin administration. A different study found that leptin-deficient ob/ob mice have a lessened locomotor response to amphetamine administration, which is corrected by leptin administration (159). These data suggest that, in addition to its metabolic function, leptin may help to modulate mesolimbic reward circuits that may relate to both palatability and substance use.
Orexins
Partially modulated by adipose-derived hormones such as leptin and ghrelin, the hypothalamic neuropeptides orexin-A and orexin-B—also referred to as hypocretin 1 and hypo-cretin 2—are important modulators of eating behavior and help to maintain energy homeostasis. The hypothalamus is the primary site of hypocretin-containing neurons, though these neurons project to other brain regions (160–162). Orexin administration has been demonstrated to increase feeding behaviors (161), while orexin antagonists have been shown to impair operant responses to food reinforcers (163) in preclinical populations.
Preclinical research has demonstrated that administration of orexin-A reinstates cocaine-seeking behaviors in a dose-dependent manner (164). Administration of orexin-A was also associated with increases in BSR, suggesting a negative regulation of reward circuits (164), consistent with orexin neurons’ activation in chronic morphine administration and precipitated morphine withdrawal (165). Similar research has demonstrated that the administration of an orexin receptor agonist abolishes reinstatement of cue-induced alcohol-seeking (166) and heroin-seeking (167) behaviors in rodents, further implicating orexin in substance-seeking behaviors.
Preclinical research also indicates a significant increase in hypothalamic orexin-containing neurons subsequent to preference conditioning for food, cocaine, or morphine, suggesting important similarities between the development of food and drug preferences (168). Whereas the number of orexin-containing neurons was positively correlated with increases in preference, no such correlations were found for any other type of hypothalamic neurons. This study additionally reported reinstatement of morphine preference subsequent to direct orexin administration to the VTA, one of the brain regions receiving projections from hypothalamic orexin neurons (168).
Orexin may directly influence DA neurons in the VTA. Pharmacologic blockade of orexin-1 receptors (Ox1r) within the VTA—but not within the paraventricular thalamus— dose-dependently attenuated cue-induced reinstatement of cocaine seeking (169). Direct administration of orexin-A or orexin-B produces locomotor-enhancing effects in mice that were prevented by prior administration of a DA receptor antagonist (170). The same study additionally demonstrated a lack of hyperlocomotion and a significantly lessened increase in DA in response to morphine (170). Increases in PFC DA subsequent to orexin-A administration to the VTA have also been reported (171). Together, these data suggest that orexin may directly influence mesolimbic DA pathways implicated in reward and drug addiction. However, further research investigating the relationship between orexinergic and dopaminergic signaling in clinical populations is needed.
Ghrelin
Ghrelin is a gastrointestinal hormone that helps to maintain energy homeostasis and may contribute importantly to the initiation of eating. Unlike leptin and orexin, which are anorexigenic, ghrelin is orexigenic and increases food intake and body weight (172). One study measured ghrelin levels in the plasma of healthy controls during a 24-hour period and found significant increases in ghrelin levels prior to meal initiation followed by significant decreases after consumption (173). Reduced levels of circulating ghrelin have been reported in obese individuals, with an inverse correlation between BMI and ghrelin levels observed (174). Interestingly, preclinical research suggests that whereas ghrelin administration increases the motivation to eat, it does not alter perceived food palatability (175).
Although ghrelin is primarily synthesized in the stomach, recent research suggests that it may also mediate feeding behaviors via direct action on certain brain regions. Preclinical research has identified a ghrelin receptor, growth hormone secretagogue 1 receptor (GHSR), in the hypothalamus and VTA. Ghrelin has been linked to increased synapse formation and DA turnover in the NAcc (176). Administration of exogenous ghrelin in the VTA prompted feeding behavior, and GHSR antagonist administration reduced feeding subsequent to food deprivation (176). Direct administration of ghrelin into the VTA, but not into the NAcc, was reported to motivate behavior for sucrose reward in an operant conditioning paradigm in rats, suggesting that ghrelin signaling within the VTA contributes to incentive-motivated behavior for a food reward (177). Ghrelin administration–induced increases in motivation to eat are eliminated following pretreatment with a DA D1 receptor antagonist, suggesting that the orexigenic effects of ghrelin are mediated by DA signaling (175). Conversely, ghrelin-deficient mice display attenuated responses to chronic and acute cocaine administration, indicating that dopaminergic neurotransmission is disrupted by deletion of the ghrelin gene (178). Overall, these findings suggest that ghrelin may help to modulate the warding properties of food via interaction with DA neurons.
The Nucleus Accumbens: Opioid and Endocannabinoid Encoding of Palatability
Research suggests that opioid receptors in the NAcc region of the ventral striatum may be particularly important for the encoding of food palatability. Preclinical research suggests that DA release in the NAcc modulates excitatory NAcc neuronal activity in response to previously learned reward-associated cues, thereby increasing the likelihood of cue responsiveness (e.g., performance of behaviors learned via operant conditioning) (179). Stimulation of NAcc opioid receptors has been found to increase food intake (180). Administration of opioid receptor antagonists, such as naloxone or naltrexone, extinguishes previously established preferences for sweetened versus unsweetened water in rats, whereas morphine has been demonstrated to enhance palatability and preference for sweet food (180,181). Importantly, such preclinical data demonstrate opioid involvement in the palatability—or reward value—encoding of food that does not appear to directly affect caloric intake. Rather, the opioid system may be involved in general reward processing, as opposed to specific appetitive control. These data nonetheless suggest shared neurobiologic mechanisms in eating and substance-use behaviors. Despite evidence implicating the opioid system in eating behaviors, pharmaceutical challenge studies of opioid receptor antagonists such as naltrex-one have yielded equivocal results in human populations, and further research is needed to establish appropriate pharmacotherapies for the treatment of BED.
Preclinical research has identified two distinct populations of NAcc neurons responsive to food consumption: a group of neurons displaying primarily excitatory responses to increased palatability (i.e., increased sucrose) and a separate group of neurons displaying primarily inhibitory responses prior to initiation of feeding behaviors that does not appear to be related to palatability (182). This finding is consistent with other preclinical research demonstrating increases in nonappetitive food intake subsequent to NAcc inhibition (183). One possible interpretation of these data is that—in addition to neurons encoding for reward—a group of NAcc neurons may also be implicated in general habit formation or basic motor control of feeding behaviors, independent of palatability, although this hypothesis requires further testing. These data further support the hypothesis that the NAcc is an important brain region for the encoding of palatability as well as the initiation of feeding responses, and highlight similarities between eating and substance-use behaviors.
Human and animal studies also implicate the endocannabinoid system (composed of cannabinoid receptors, endocannabinoids, and associated enzymes) in eating behaviors (184,185). The endocannabinoid system is composed of two endogenous ligands, anandamide (arachidonoylethanolamide) and 2-arachidonoylglycerol (2-AG), and two cannabinoid receptors, CB1 and CB2 (186). Cannabinoid receptors in the NAcc have been implicated in appetitive behavior.
Preclinical research suggests that CB1 receptors partially mediated by leptin (187) are involved in the presynaptic modulation of release for the neurotransmitters GABA, glutamate, DA, noradrenaline, and serotonin (184,188) and has identified cannabinoid receptors (CB1/2) in the limbic forebrain, striatum, and NAcc (reviewed in Ref. (189)). Colocalization of opioid and CB1 receptors in the striatum has also been reported (reviewed in Ref. (189)). Preclinical investigations have additionally reported increases in feeding behaviors subsequent to administration of delta9-THC and anandamide (an endogenous cannabinoid neurotransmitter) (reviewed in Ref. (189)). Cannabinoids have long been associated with rewarding psychotropic effects and are additionally associated with increases in food intake. In addition to cannabinoid-induced increases in feeding behaviors, studies have implicated endogenous cannabinoids in the experience and encoding of food-associated reward. For example, direct anandamide administration to the NAcc shell has been found to significantly enhance “hedonistic” reward and increase feeding behaviors in rats (189). Elevated anandamide blood levels have been reported in individuals with AN and individuals with BED, whereas no such elevation has been reported in individuals with BN (186). Interestingly, a recent study suggests that endocannabinoid administration increased gustatory nerve response to sweeteners in a concentration-dependent manner without affecting responses to other tasting compounds (e.g., salty, sour, bitter, and savory) (190). The cannabinoid 1 receptor (CB1R) is thought to be a promising drug target for antiobesity medication, and the CB1R antagonist/inverse agonist, rimonabant, has been shown to significantly reduce body weight in humans; however, it is associated with psychiatric side effects including anxiety, depression, and suicidal tendencies (191,192). Recent preclinical research suggests that the neutral CB1R antagonist NESS0327 is as effective as rimonabant in reducing weight gain and food intake and lacks potentially harmful effects on anxiety and motivation (193).
Prefrontal Cortex
Research from neuroimaging, neurocognitive, and lesion studies implicates prefrontal cortical modulation of eating behaviors. Frontotemporal dementia (FTD), a degenerative disorder involving atrophy of frontal, insular, and temporal cortical regions, is characterized by behavioral changes in eating and sexual behaviors (194) as well as deficits in insight, empathy, and social interaction (194,195). Clinically reported changes in eating behaviors associated with FTD include increases in weight, food cravings/obsessions, and gluttony (195). Similarly, a recent study found that individuals with FTD meeting criteria for “gluttonous” overeating during “all-you-can-eat” 1-hour meal sessions had significantly increased atrophy of the OFC, right ventral insula, and striatum (196).
Evidence derived from positron emission tomography (PET) research additionally suggests a relationship between frontal lobe activity and eating behaviors. In weight loss studies, “successful” as compared to “nonsuccessful” weight-loss dieters/maintainers had significantly greater activation in dorsal prefrontal cortex (DPFC), dorsal striatum, and anterior cerebellar lobe brain regions following meal consumption (197) and food visualization (198). Conversely, nonsuccessful dieters had significantly greater OFC activation following meal consumption (197). These data suggest differential modulation of eating behaviors by prefrontal regions. Further investigation is required to fully understand interactions between PFC regions in relation to eating behaviors.
Consistent with the finding that greater dietary restraint is negatively correlated with OFC activation and positively correlated with DPFC activation, one randomized, double-blind, parallel group study using repetitive transcranial magnetic stimulation found reduced self-reported craving sensations in response to exposure to craving-inducing foods subsequent to left dorsolateral prefrontal cortex (dlPFC) stimulation (199). dlPFC stimulation has also been reported to be effective in reducing cravings for nicotine, alcohol, and cocaine, suggesting potentially similar neuro-biologic mechanisms for food and drug craving (reviewed in Ref. (200)).
Neurocognitive research additionally implicates frontal lobe involvement in binge eating. Similar to impulse control–related disorders (e.g., SUDs, PG), deficits in decision making have been reported in BED and obesity. In a sample of 41 healthy adult women, a tendency to overeat in response to stress and higher BMI both significantly predicted poorer IGT performance (201). In other studies, obese (vs. nonobese) individuals also performed significantly worse on the IGT and showed no improvement in performance over time (201–203).
Similar decision-making deficits have been reported in both AN and BN. Individuals with AN have been reported to perform significantly worse on the IGT and displayed significant reduction in skin conductance response in comparison to healthy controls and recovered AN patients (ANR) (204). In contrast, Liao et al. (205) reported that while BN individuals similarly performed poorly on the IGT, unlike individuals with AN, they showed no reduction in skin conductance response. Similar performance deficits among individuals with BN were also reported in a study using the Game of Dice Task (206), a decision-making assessment that, unlike the IGT, provides explicit information of reward-loss contingencies (207).
Serotonin (5-HT)
Increases in both exogenous and endogenous serotonin (5-HT) are associated with a reduction of food intake and weight gain, and an increase in energy expenditure (208). In relation to eating behaviors, research has focused on 5-HT and the hypothalamus. 5-HT neurons located in the dorsal raphe nucleus receive direct projections from hypothalamic orexin neurons and express orexin-A and orexin-B receptors (reviewed in Ref. (209)). Hypothalamic 5-HT may in part mediate the experience of satiety. Medial hypothalamic 5-HT is implicated in the temporal management of eating behavior, in particular with meal termination, as opposed to initiation. Preclinical research has demonstrated that d-fenfluramine (d-FEN)—also known as “Fen-Phen” when combined with phentermine—an exogenous agent that increases 5-HT release while also blocking reuptake, may exert its anorexigenic effects via 5HT2C receptor activation of proopiomelanocortin (POMC) neurons in lateral hypothalamic regions (210). Further research is needed to establish the precise role of the central melanocortin system in the regulation of food intake. Such data may help to develop alternative pharmacotherapies for BED and other eating disorders (210).
5-HT is also thought to be implicated in food preference. For example, preclinical studies have demonstrated that the injection of either exogenous 5-HT or drugs that increase 5-HT availability (such as fluoxetine) into the medial hypothalamus selectively inhibits carbohydrate intake but has no significant effect on fat or protein intake (211). Conversely, elevated levels of tryptophan (TRP), a 5-HT amino acid precursor and hypothalamic 5-HT, are associated with high-carbohydrate intake (reviewed in Ref. (208,212)).
SSRIs have been shown to be efficacious in treating eating disorders with fluoxetine approved by the Food and Drug Administration for the treatment of BN and sibutramine approved for the treatment of obesity (213). Some research suggests that SSRIs are effective in targeting binge eating, psychiatric, and weight symptoms (214), although the effectiveness and duration of these medications remain under debate. In an open-label study, Leombruni et al. (215,216) reported that BED patients who display decreased binge eating and weight loss following initial SSRI administration maintained these beneficial effects for 6 months with continuation of SSRI treatment. In a randomized, double-blind, 12-week study of escitalopram versus placebo for the treatment of individuals with comorbid BED and obesity, individuals receiving high-dose escitalopram treatment had significantly greater reductions in weight, BMI, and total global illness severity (217). However, no significant between-group differences were found for the variables reduction of binge episodes, reduction of days with a binge episode, and reduction of obsessive–compulsive features of BED. In a 2-year follow-up of fluoxetine-treated individuals with BED, no significant improvements in BED symptoms were reported, despite significant improvements in depressive symptoms (218).
Conclusion
Binge eating and comorbid obesity are increasingly common phenomena with wide-ranging public health implications. Recent neurobiologic findings, such as the involvement of the adipose-derived hormone leptin in the dopaminergic reward system, suggest that BED is a brain-based disorder that may share many of the same neurobiologic features as SUDs. Such findings have important treatment implications, and further investigation is required in order to optimize treatment interventions.
COMPULSIVE SEXUAL BEHAVIOR
CSB is characterized by excessive engagement in normative sexual behaviors. Not included in the DSM-IV, CSB is often referred to as sexual addiction, hypersexual disorder (the proposed diagnostic entity for DSM-5), or sexual impulsivity.
Clinically relevant sexual behaviors may be divided into paraphilic and nonparaphilic behaviors. In paraphilic sexual behaviors, there is a disturbance in the object selection (e.g., an animal, unwilling person, inanimate object). In nonparaphilic sexual behaviors, the individual engages in socially normative sexual behaviors in an excessive, obsessive, or compulsive manner, without a disturbance of object choice. Paraphilic disorders are a distinct category of disorders, already included in the DSM-IV-TR, and are outside the scope of this chapter.
Epidemiology
There has been no systematic epidemiologic study of CSB, although estimates of 5% to 6% in the adult population have been reported (219,220). The majority of research on CSB has been conducted using predominantly male clinical populations. Co-occurring mood disorders (e.g., early-onset dysthymia), anxiety disorders, SUDs, ICDs, and ADHD have been reported in association with CSB (221,222).
Phenomenologic similarities between CSB and SUDs have been described. Individuals suffering from CSB often report feeling “out of control.” Estimates of co-occurrence rates for SUDs and CSB range from 25% to 71% (221). CSBs are aimed at reward seeking and anxiety reduction. Individuals with CSBs report feelings of regret and fear over losing loved ones or employment as a result of their behaviors (223).
Defining the Disorder
Nonparaphilic impulsive or compulsive sexual disorders are not specifically listed in the DSM-IV-TR. CSB can therefore be classified as either an impulse-control disorder NOS or a sexual disorder NOS. As with other ICDs, CSB can be conceptualized along an impulsive–compulsive spectrum or as an addictive disorder (221,224). Coleman (225) has identified seven distinct CSB categories, all with their own unique constellation of symptoms: compulsive cruising and multiple partners, compulsive multiple love relationships, compulsive sexuality in a relationship, compulsive use of erotica, compulsive autoeroticism, compulsive use of the Internet, and compulsive fixation on an unattainable partner. When assessing sexual behaviors, Kafka (226) redefined Kinsey et al. (227) original frequency measure to the total sexual outlet as number of orgasms/number of weeks—a total sexual outlet score ≥7 is associated with both paraphilic and nonparaphilic (i.e., CSB) disorders. Other instruments, such as the Minnesota Impulsive Disorders Inventory (228) and clinician-designed “hypersexuality” (i.e., CSB) questionnaires (229), more closely resemble the diagnostic criteria for SUDs and other ICDs, such as PG: maladaptive preoccupation with sexual behaviors/thoughts; repetitive sexual fantasies causing distress or associated with a loss of control; repetitive sexual urges causing distress or associated with a loss of control; repetitive engagement in sexual behaviors ( including masturbation, telephone sex lines, and phonography) causing distress or associated with a loss of control.
Neurocircuitry
To our knowledge, there have been no functional imaging studies of CSB performed to date. In human and preclinical populations, bilateral temporal lesions are associated with placidity, hyperorality, visual agnosia, and hypersexuality (230). Together, this constellation of symptoms has been termed Klüver-Bucy syndrome and has also been observed in amygdala-lesioned patients (221). Extremely rare in humans, Klüver-Bucy syndrome’s associated hypersexuality, although infrequent, suggests an involvement of temporal lobe function in CSB and other paraphilia-related disorders. Klüver-Bucy syndrome is most commonly associated with Alzheimer disease, herpes simplex encephalitis, ischemia/anoxia, and temporal lobectomies.
Neurostructure
There has been one DTI study of white matter microstructures in CSB. Miner et al. (231) reported significantly higher mean diffusivity in a superior frontal region among individuals with CSB in comparison to controls. Correlational analyses revealed a significant negative association between fractional anisotropy (FA) within an inferior frontal region and self-reported impulsivity. However, given the small sample size of this study (i.e., eight patients with CSB and eight controls), further research is needed.
Neurochemistry
DA, 5-HT, NE, and the opioid system contribute to human sexual behavior though systematic studies of their involvement in CSB are lacking. Open-label prescriptions of lithium, tricyclic antidepressants, SSRIs, nefazodone, naltrexone, and atypical antipsychotics have all been used to treat CSB (232), but their efficacy in treating CSB remains to be systematically examined. At present, most of the data on pharmacologic treatment for CSB are only from individual case reports, and more research is needed to identify empirically validated pharmacotherapies.
5-HT is implicated in sexual functioning and desire, and sexual dysfunctions, such as decreased libido, anorgasmia, and delayed ejaculation, are reported as adverse effects of SSRI treatment (219,233). There is mixed evidence to support the efficacy of SSRIs in treating CSB symptoms. In a randomized clinical trial, homosexual men with sexually compulsive behavior reported a greater reduction reduced sexual desire after taking citalopram, without a lessening in sexual satisfaction, than did individuals taking placebo (234). It is presently not clear whether the effectiveness of SSRI administration in reducing CSB symptoms can be attributed to an actual reduction of sexual thoughts or to the sexual side effects of the medication (219). Positive results have been noted with nefazodone, a phenylpiperazine antidepressant that antagonizes 5-HT receptors and influences 5-HT and NE reuptake, in reducing sexual thoughts without the presence of substantial sexual side effects over the long term (219). Because sexual side effects may deter CSB patients from continuing SSRI treatment, nefazodone may be particularly beneficial in treating CSB. However, controlled trials are needed to further determining the efficacy and tolerability of nefazodone in treating CSB.
Pharmacologic tolerance to SSRI treatment has been reported in men with CSB and ADHD co-occurs with CSB. Kafka and Hennen (235) examined the effect of psycho-stimulant augmentation during SSRI treatment in a sample of men with paraphilic or paraphilia-related (e.g., CSB) disorders. They found a significant reduction in paraphilic or paraphilia-related behaviors in response to SSRI treatment alone and also reported a significant improvement subsequent to methylphenidate SR (sustained release). These preliminary data suggest an additive effect of methylphenidate administration in CSB populations that may help to counteract pharmacologic tolerance to SSRIs, and they additionally implicate a dysregulation of the dopaminergic, serotonergic, and NE systems in CSB. However, controlled trials are needed to examine the efficacy and tolerability of these medications in treating CSB.
The opioid system may also play a role in sexual behaviors (e.g., mediate orgasm and arousal), and the endogenous opioid system may be dysregulated in CSB. In a randomized, double-blind crossover design, naltrexone (25 mg/d), an opioid receptor antagonist, or placebo was administered to a sample of 20 sexually active men over a 3-day time period (236). After 14 days, participants were administered either naltrexone or placebo (i.e., whichever they did not receive in the initial trial). As assessed via subject self-report, naltrexone administration was associated with increased sexual arousal, greater frequency of orgasms, and orgasm intensity in response to masturbatory behaviors. Topiramate, an anticonvulsant hypothesized to partially inhibit GABAergic input into the NAcc in a similar fashion to opioid antagonists (237), has also been shown alleviate symptoms of CSB although these effects were not maintained following topiramate discontinuation (232). Conversely, preliminary open-label studies of opioid receptor antagonists in CSB populations suggest possible efficacy at high doses; for example, administration of naltrexone at 150 mg/d (238) and 100 to 200 mg/d (239) have been reported to successfully reduce CSB symptoms and decrease sexual fantasies and masturbation. Together, these contradictory findings suggest the involvement of endogenous opioids in CSB although the precise relationship remains unclear. Other factors, including differences in patient populations and dosing durations, also warrant consideration.
Increased sexual desire and impulse control behaviors have been observed in patients with PD or restless leg syndrome (RLS) taking dopaminergic medications (92,240). Voon and Fox (229) estimated that 2.4% of PD patients taking DA agonists meet the criteria for hypersexuality or pathologic sexual behavior. In a study of 70 RLS patients without comorbid PD, 5% of respondents reported a high level of sexual desire and 4% reported that their desire had increased subsequent to taking dopaminergic medication (pramipexole, ropinirole, levodopa, and pramipexole) (240). None of the patients with high levels of sexual desire had a personal or family history of CSB or sexual paraphilia. However, impulse control behaviors (including hypersexuality) have been associated with demographic and clinical features of PD independent of medication, supporting the notion that multiple factors contribute to the development of ICDs in PD (92,241). Further research is needed to examine the potential role of DA in the pathophysiology of CSB and other sexual behaviors in PD and RLS.
Conclusion
CSB has been clinically acknowledged for years but is not listed in either the DSM-IV-TR or DSM-5. Like other behavioral addictions, CSB is negatively associated with distress and may interfere with personal and professional life. Little is currently known about the neurobiology of CSB, and further research studies are needed to determine effective therapeutic interventions.
PROBLEMATIC INTERNET USE
Not currently included in the DSM, PIU or “Internet addiction” is underresearched and very rarely addressed clinically. PIU is thought to be characterized by excessive or poorly controlled urges and a maladaptive obsession with the Internet (242). While moderate Internet use may enhance one’s quality of life by widening social circles and enhancing psychological well-being (243–245), excessive Internet use may be problematic and impact negatively on daily function, family relationships, and emotional stability (243,244,246). Moreover, PIU may be positively associated with SUDs, incarceration and legal troubles, and poor physical and mental health (242,247–250). As with other ICDs such as compulsive shopping, PIU involves excessive engagement in socially normative activities. As such, it may be hard to identify, and patients may be reticent to disclose excessive Internet-use behaviors, due to embarrassment, lack of awareness, or ambivalence over reducing their use.
Epidemiology
There are no uniformly agreed-upon diagnostic criteria for PIU. Definitions of PIU have often been based on DSM-IV criteria for PG (251–253). Of these, Young’s Internet Addiction Scale (254) is often used and has demonstrated sufficient reliability (255–257). Based on the DSM-IV definitions of SUDs and PG, Young (254) proposed the following criteria for “Internet addiction”: withdrawal, tolerance, preoccupation with the Internet, longer than intended spent on the Internet, risk to significant other relationships and/or employment, lying about Internet use, and repeated, unsuccessful attempts to stop Internet use. The lack of a universal assessment tool may contribute to the wide range of prevalence estimates reported among adolescents (4.0% to 19.1%) and adults (0.7% to 18.3%) (reviewed in Ref. (258)).
In terms of comorbidity, PIU frequently co-occurs not only with SUDs (259–261) but also with various psychiatric conditions including impulse-control, mood, and personality disorders (253,255,262,263).
Neurocircuitry
While evidence remains scarce and limited, there is emerging research examining brain function among individuals with PIU. In an fMRI study, increased resting state regional homogeneity involving the right frontal region, left superior frontal gyrus, right cingulate gyrus, bilateral parahippocampus, and other regions was observed among PIU individuals (vs. controls) (264). Other evidence suggests differences in brain function during cognitive tasks. Greater activation of the anterior and posterior cingulate cortices during the Stroop color–word interference task has also been observed (265). Interestingly, greater anterior cingulate cortex (ACC) activation was associated with slower incongruent reaction time and more severe scores on the Young’s Internet Addiction Scale across all participants (265). In a monetary gain and loss guessing task, increased activation of the OFC to gain trials and decreased ACC to loss trials was observed among PIU compared to controls, suggesting sensitization to reward and densization to loss (266).
Neurostructure
A recent VBM study reported decreased gray matter density in the left ACC, left posterior cingulate cortex, left insula, and left lingual gyrus among individuals with PIU in comparison to age- and gender-matched comparison participants (267). Similarly, an independent study reported among adolescents with “Internet addiction” relatively decreased gray matter volumes in the left anterior cingulate—as well as in regions of the dorsolateral and orbitofrontal PFC, supplementary motor area, and cerebellum (268).
FA—a widely used measure of white matter integrity based on DTI—was increased within a region of the left internal capsule and decreased within a region of the right parahippocampal gyrus among adolescents with “Internet addiction” (vs. controls) (268). By contrast, Lin et al. (269) reported widespread impairments in white matter microstructures—as indexed by decreased FA and increased radial diffusivity—encompassing callosal, association, and projection fiber tracts among adolescents with “Internet addiction.” Together, these data suggest involvement of white matter microstructures in the pathophysiology of PIU. However, given the differences in anatomical loci reported between studies, further research into the precise relationship between scalar indices of white matter microstructural integrity (e.g., FA) and PIU are warranted.
Neurochemistry
There have been two ligand-based studies of dopaminergic functioning among individuals with PIU. A small-scale single-photon emission computed tomography (SPECT) study reported reduced DA transporter expression within the striatum among young adult males who used the Internet almost every day and spent more than 8 hours per day online, compared to matched controls (270). Another small-scale study using [11C]raclopride during PET scanning reported that adult males with PIU had reduced DA D2 receptor availability in the bilateral caudate and left putamen compared to controls and that the degree of DA receptor availability was inversely correlated with the severity of PIU (271). These preliminary findings suggest that PIU may be associated with dopaminergic neural systems in a fashion similar to substance-related addictions.
Genetic Polymorphisms in PIU
The short allelic variant of the gene encoding the serotonin transporter (SS-5HTTLPR) has been reported to be more prevalent among 91 adolescent males with PIU compared to 75 matched controls (272). Within the PIU group, the authors reported that those with the SS-5HTTLPR showed higher harm avoidance and scored higher on Young’s Internet Addiction Scale compared to those expressing other 5HTTLPR allelic variants. The T-variant (CC genotype) polymorphism of the nicotinic acetylcholine receptor subunit alpha-4 (CHRNA4) gene has also been implicated, with increased frequencies among individuals with PIU compared to controls; further analyses revealed that this finding was driven by females, suggesting sex-specific genetic effects (273). Replication of these findings is needed in future studies before definitive conclusions can be drawn.
Gender Differences
As with SUDs, significant gender differences have been reported in PIU. In a Taiwanese study of Internet behaviors amongst adolescents (n = 2,114), higher levels of Internet addiction were associated with higher rates of ADHD and depression across genders. However, higher rates of aggression were associated with increased severity of PIU only among males (274). Social phobia was also associated with Internet addiction, although not significantly after accounting for ADHD, depression, and hostility symptoms. These data suggest that ADHD, depression, and aggression may be vulnerability factors for PIU and that social phobia may be a negative consequence of PIU (274). Some data suggest that the proportion of Internet users is slightly higher among men than among women, with men being more likely to have PIU (275–277), although this gender gap may be fading (278).
Conclusion
Although not currently included in the DSM-IV, PIU is associated with significant psychological distress and has been increasingly researched in recent years. Preliminary evidence suggests neurobiologic similarities with SUDs; however, further research is needed to support this hypothesis.
PROBLEMATIC VIDEO GAME PLAYING
Although some (279) might argue that problematic video game playing (PVG) or “video game addiction” is part of the PIU and both should be considered under the umbrella term pathologic technology use, the two conditions may relate to different clinical and health-related characteristics and, as such, merit separate consideration. PVG is both similar to and distinct from other behavioral addictions such as PG and PIU in its availability and use of visual and auditory rewards, and these differences may contribute to PVG’s unique features (280,281). However, previous research on PVG has often included online games; thus, video game findings cannot be clearly separated from Internet findings based on existing data.
Epidemiology
PVG has been linked to low social competence, low academic performance, and, in the case of violent video games, aggression or violence (258). Extreme cases of PVG have been cited as a possible contributing factor in deaths in South Korea (282) and the United States (283). While no DSM-based diagnostic criteria exist, similar to PIU, assessment tools for PVG are often based on the DSM-IV definitions for SUDs and PG (284). A range of prevalence estimates has been reported for adolescent populations (4.2% to 20.0%), with published adult estimates (11.9%) falling in this range (258).
Psychiatric comorbidities in individuals with PVG are poorly researched. Preliminary findings suggest links with ADHD (285), mood disorders (255,286), and SUDs (286,287), though negative results have also been reported (288).
Neurocircuitry and Structure
The ventral striatum has been frequently implicated in fMRI studies of PVG. In a recent MRI study, both structural and functional differences were observed in frequent (>9 hours per week) compared to infrequent (≤9 hours per week) gamers (289). Greater left ventral striatal gray matter volume was observed in frequent as opposed to infrequent video gamers, and volume of this region was negatively correlated with deliberation time during the Cambridge Gambling Task. Activation in the same region was also greater during feedback of loss compared to no loss during performance of a monetary incentive delay task among frequent compared to infrequent video gamers.
Other brain regions have also been implicated in PVG. Among 19 healthy male adults who played a novel video game for 60 minutes per day for 10 days, increased activations to video game versus neutral stimuli were observed in the left inferior frontal gyrus, left parahippocampal gyrus, right and left parietal lobe, right and left thalamus, and right cerebellum (290). Greater activation of the right OFC, right NAcc, bilateral anterior cingulate, medial frontal cortex, right dlPFC, and right caudate in response to video game cues has also been reported among adult males who spent more than 30 hours per week playing World of Warcraft (a Massive Multiplayer Online Role-Playing Game), in comparison to nonheavy players (<2 hours per day) (291). Subsequent studies have similarly reported greater activation in these regions among individuals with current PVG (292) and among individuals in remission from online PVG (293) in response to video game cues, in comparison to controls. However, interpretation of existing studies is complicated by methodologic issues such as the use of online games. Importantly, most studies looked at frequent versus infrequent players, limiting the generalizability of findings to PVG.
Neurochemistry
In an early study using the D2-like DA receptor radioligand [11C]raclopride during PET scanning, findings consistent with increased release of DA, particularly in the ventral striatum, were observed following a 50-minute video game play in eight healthy adult males (294). A more recent study using SPECT suggests that DA release in the ventral striatum during a motorbike riding computer game (295) is comparable to that induced by psychostimulant drugs such as amphetamine (296) and methylphenidate (297). Individuals with PVG (>30-hour StarCraft per week) reported decreased craving for video game play, reduced total game play time, and reduced cue-induced brain activity in the dlPFC following 6 weeks of bupropion (a drug with dopaminergic/noradrenergic reuptake blocking properties), compared to pretreatment (298).
Genetic Polymorphisms in PVG
Limited research regarding genetic polymorphisms in PVG exists. Polymorphisms of the TaqIA1 allele of the DRD2 receptor gene and Val158Met in the catecholamine-o-methyltransferase (COMT) gene have been implicated in preliminary studies of PVG. TaqIA1 and low-activity (COMTL) alleles were more prevalent among 79 problematic Internet video game players compared to 75 controls (299), and the DRD2TaqIA1 allele was associated with reward dependence among problematic Internet video game players. Further research with respect to the genetic factors relating to PVG is needed.
Gender Differences
While adolescent boys are more likely to endorse more PVG symptoms (285), a recent study suggests that video gaming is associated with measures of aggression and violence amongst adolescent girls. However, no associations with negative health measures were observed amongst adolescent boys suggesting that video gaming may be a normative behavior amongst boys, at least in the current U.S. culture. Research pertaining to gender-related differences in adults has yielded mixed results (258).
Conclusion
Preliminary evidence suggests alterations in ventral striatal structure and function among individuals with PVG and possible dopaminergic and serotonergic involvement in video gaming behaviors. However, no formal diagnostic criteria (i.e., DSM criteria) exist for PVG, limiting the interpretation of existing findings from studies of “heavy” versus “light” video game players.
COMPULSIVE BUYING DISORDER
Classically referred to as “oniomania,” compulsive shopping or buying has been clinically recognized for at least a century (300) (reviewed in Ref. (301)). However, little is known about the pathophysiology of compulsive buying disorder (CBD).
Neurocircuitry
To our knowledge, only one imaging-based study has been conducted among individuals with CBD. Raab et al. (302) compared blood oxygen level dependent in fMRI signal responses between individuals with CBD currently undergoing treatment with a psychiatrist or psychologist versus those of healthy controls during performance of a multiphase purchasing task (303). During an initial product presentation phase, CBD individuals showed stronger NAcc activity compared to controls. During the subsequent price presentation phrase, CBD individuals showed attenuated activation of the insula and anterior cingulate (ACC) compared to controls. In contrast, individuals with CBD had increased ACC activity while making purchasing decisions, in comparison to controls.
Neurochemistry
Selective Serotonin Reuptake Inhibitors
Pharmacologic studies suggest certain similarities with SUDs, in particular with respect to the potential efficacy of naltrexone in CBD populations. Consistent with findings from other studies conducted among individuals with ICDs such as CSB, a substantial placebo effect has been reported in pharmacologic treatment studies of SSRIs for CBD. Positive results for citalopram have been reported in a small open-label trial (304). However, double-blind studies have reported no between-group differences in outcome with fluvoxamine (305) and escitalopram (306). These findings from controlled studies raise questions regarding the clinical utility of SSRIs in the treatment of CBD.
Opioid Antagonists
There have been four case reports of successful naltrexone treatment in CBD (307,308). Kim (307) has reported successful CBD treatment with naltrexone (100 mg/d) in one individual with comorbid BN (which was also responsive to naltrexone treatment). Grant (308) reported three cases of successful high-dose naltrexone (100 to 200 mg/d) treatment for CBD.
Conclusion
The prevalence of CBD within community and clinical settings remains unclear. CBD is associated with significant psychological distress, and preliminary research suggests altered neurofunctional responses to shopping stimuli. However, very few treatment studies exist. Future research should further explore the efficacy of medications such as naltrexone using double-blind, placebo-controlled trials.
KLEPTOMANIA
Historically, the terms “shoplifting” and “kleptomania” have been used interchangeably but significant differences exist between the two. Individuals with kleptomania differ from typical shoplifters in that they do not steal for personal gains but for symptomatic relief (20). Individuals with kleptomania suffer from a diminished ability to inhibit impulses to steal unnecessary or unwanted items, resulting in negative personal and professional consequences and experiences of regret and distress (309). DSM-IV diagnostic criteria for kleptomania reflect these aspects and include an increase in tension prior to theft followed by subjective pleasure/relief associated with theft (20).
Epidemiology
Kleptomania generally begins in adolescence or early adulthood and appears to be more common in women than men (310). The natural history of kleptomania disorder may be chronic or acute (310). As with adolescent gambling, kleptomania is by definition illegal and therefore poses specific negative consequences, such as incarceration, in addition to the more general negative consequences to personal and professional life. The necessarily illegal nature of these behaviors may increase both experiences of shame as well as reluctance to seek treatment. Although kleptomania has been reported to have a prevalence approaching 1% (311), the disorder has been omitted from major psychiatric epidemiologic studies, so its true prevalence remains unclear.
Mood disorders, OCD, panic disorder, separation anxiety disorder, body dysmorphic disorder (BDD), and other ICDs have been associated with kleptomania (310), and an association with first-degree relatives with substance-use problems suggests a shared genetic vulnerability between SUDs and kleptomania (312).
Neurocircuitry
Neurocognitive and neuroimaging research suggest frontal lobe involvement in kleptomania. To our knowledge, only one multisubject imaging study has been performed in kleptomania, although imaging data from case reports exist. Using DTI, one study reported reduced white matter integrity in inferior frontal regions in kleptomania versus controls (313). Performance deficits in neuropsychological tasks associated with prefrontal regions (i.e., Wisconsin Card Sorting Test performance) have been found to correlate with kleptomania symptom severity (314).
Lesion-based case report studies also suggest frontal lobe involvement. Aizer et al. (315) reported kleptomania subsequent to closed-head frontotemporal lobe blunt trauma in two male patients; kleptomania symptoms were reduced by combined citalopram and cognitive behavioral therapy in the first patient and naltrexone in the second patient. Other case studies have similarly reported positive results for SSRI (316,317) as well as topiramate (237,316) treatment in the reduction of kleptomania symptoms following frontal lobe lesion.
Neurochemistry
Findings regarding serotonergic dysfunction in kleptomania have been inconsistent. Successful fluoxetine treatment of kleptomania has been reported in case studies (318,319) although findings from a small double-blind, placebo-controlled clinical trial suggest that response rates during open-label treatment are not better maintained by escitalo-pram than placebo (320).
Opioid antagonists, such as naltrexone, have also shown some efficacy in reducing kleptomania symptoms in case studies (307,321). An open-label trial of naltrexone treatment for kleptomania found significant decreases in urge intensity and frequency subsequent to 12-week naltrexone administration (322).
Conclusion
Preliminary evidence suggests neurobiologic similarities between kleptomania and SUDs. Individuals with kleptomania display alterations in frontal white matter micro-structures that are similar in nature to those reported among individuals with SUDs and also respond to medications such as naltrexone that have historically been used to treat substance addictions. However, further research into the efficacy of different medications as well as into the biology of this disorder is needed.
TRICHOTILLOMANIA
Hair twirling, lip and nail biting, skin picking, and other mildly uncomfortable or painful behaviors are common among the general population and are generally benign. Excessive engagement in such behaviors can have long-term medical consequences. First described by Hallopeau in 1889 (323), trichotillomania remains an ineffectively treated disorder, and descriptive studies suggest that it is a heterogeneous disorder not well characterized by the current diagnostic criteria (324). Trichotillomania involves the pulling out of hair, most frequently from the scalp, although axillary, pubic, and perirectal regions may also be targeted.
Trichophagia (eating hair) may co-occur with trichotillomania. Resultant trichobezoars (hair balls) may cause gastrointestinal obstruction requiring surgical intervention (325). If untreated, trichobezoars may cause anemia, abdominal pain, hematemesis, nausea, vomiting, and bowel obstruction or perforation. However, the relationship between trichobezoars and trichotillomania has not yet been systematically assessed (325). Interpersonal consequences (i.e., negative effects to personal and professional life) (20) have additionally been reported.
Epidemiology
The duration of trichotillomania varies widely. Onset generally occurs in adolescence and may present as chronic and persistent across the life span or may abate without treatment (20). Community sampling suggest lifetime prevalence rates to be equal for both gender (326), although trichotillomania appears to be more prevalent among females in clinical settings (327,328). In addition to trichophagia, co-occurring mood disorders, anxiety disorders, SUDs, OCD, eating disorders, personality disorders, and mental retardation have been reported in trichotillomania (20,329). Alopecia also commonly occurs with trichotillomania.
OCD and Trichotillomania
Trichotillomania is classified in the DSM-IV-TR (20) as an ICD. This classification is under considerable debate with support for the reclassification of trichotillomania as an OCSDs category, along with OCD, as there appear to be shared characteristics between the two disorders (19). However, while elevated levels of OCD have been reported in subjects with trichotillomania and their first-degree relatives, the internal experiences of OCD and trichotillomania appear quite different: compulsions are usually performed to relieve anxiety due to distressing obsessional thoughts that are ego dystonic, whereas hair pulling is often in response to urges or desires to pull that are ego syntonic and is often reported as a hedonic experience (23). This difference suggests that trichotillomania may have a different pathophysiology than does OCD. Moreover, phenomenologic aspects of trichotillomania seem similar to those of SUDs. Hair pulling is generally preceded by a sense of tension or experience of craving, and individuals report feeling unable to inhibit behaviors and report experiences of pleasure/relief during hair pulling. Grant et al. (23) have therefore suggested that two distinct pathophysiologies may underlie trichotillomania: one more resembling OCD and the other more resembling SUDs.
Neurocircuitry
A SPECT analysis of female identical twins suggests that temporal pole abnormalities may be implicated in trichotillomania, with greater abnormalities associated with more severe symptomatology (330). In contrast, an fMRI study reported no between-group differences in corticostriatal function (331).
Neurostructure
Structural neuroimaging studies have reported reduced left inferior frontal gyrus and left putamen volumes in trichotillomania (vs. controls) (332,333). These abnormalities are distinct from those observed in OCD. In particular, reduced caudate volume, reported in OCD, has not been consistently found in trichotillomania. However, there has also been one report of no alterations in caudate volumes among women with OCD in comparison to women with trichotillomania or in comparison to healthy controls (334). In the only published DTI study conducted among individuals with trichotillomania, Chamberlain et al. (335) reported decreased FA in regions of the anterior cingulate, presupplementary motor area, and temporal cortex.
Neurotransmitters
SSRIs—an effective treatment for OCD—have been shown to alleviate some of the behaviors of trichotillomania; however, these findings are not consistent across individual patients, suggesting that there may be more than one pathophysiology in trichotillomania (23). Pharmacologic research with SSRIs has yielded conflicting results. A meta-analysis suggests that while clomipramine was more efficacious than was placebo in reducing trichotillomania severity, no significant results were observed with other SSRIs including fluoxetine and sertraline (336). Additionally, the effectiveness of serotonergic drugs in treating trichotillomania has been reported to gradually decrease over time (334).
Naltrexone, an opioid receptor antagonist used to treat alcohol and opiate dependence, has been found to effectively treat features of trichotillomania (337). Naltrexone is not effective in treating OCD symptoms, suggesting a difference in the underlying biologies of the disorders.
Conclusion
Trichotillomania is associated with psychiatric and medical problems, including depression, social isolation, and alopecia. Although traditionally conceptualized as an ICD with strong similarities with OCD, clinical, phenomenologic, and neurobiologic research has identified important differences between trichotillomania and OCD, suggesting different pathophysiologies. Similarities between trichotillomania and SUDs require further investigation, as they might carry important implications for patient care.
PATHOLOGIC SKIN PICKING
PSP—sometimes referred to as neurotic excoriation—is characterized by pathologic attention to, and extended duration of, skin picking behavior that is impulsive, ritualistic, and repetitive (338). No single body area is uniquely associated with skin picking behaviors, and any part of the body may be targeted. Individuals with this disorder may use a variety of implements to pick skin: tweezers, fingernails, pins, etc. Skin picking is listed in the DSM-IV-TR‘(20) under stereotypic movement disorder (SMD) with self-injurious behavior (SIB). SMD is defined as repetitive, seemingly goal-directed but nonfunctional motor behavior, resulting in self-inflicted injury or disruption to daily activities (20). SMD is most prevalent in individuals with mental retardation, and approximately 25% of adults institutionalized for mental retardation meet criteria (339,340).
The compulsive and repetitive behaviors seen in PSP, particularly in those individuals without mental retardation, share similarities with other grooming disorders such as trichotillomania. Both skin picking and trichotillomania are generally done in isolation or only in the presence of close family members, thus discouraging socializing. Clinical reports additionally suggest that suicidality is often a comorbid characteristic of individuals with PSP. Phenomenologically, trichotillomania and PSP appear similar (341), and this has lead to the proposed term body-focused repetitive behaviors (BFRBs) (342).
Epidemiology
As in cases of other ICDs, individuals with PSP may feel ashamed of their behaviors and therefore be reluctant to seek psychological or medical treatment. Two community prevalence studies have found that PSP is fairly common. In a nonclinical sample, 63% of respondents reported engagement in some form of picking, and 5.4% met the criteria for PSP (343). Another study reported that 10% of respondents to a telephone interview reported having noticeable skin damage that was not attributable to a medical condition, and 1.4% met the criteria for PSP (344). Data derived from clinical populations estimate that 47.5% of treatment-seeking individuals had an onset of PSP prior to 10 years of age (345).
PSP appears to be a chronic, often lifelong, condition that is associated with adverse medical and psychiatric outcomes. In contrast to trichotillomania (346), age of onset does not appear to have a substantial influence on PSP phenomenology or disease course (345). The finding that almost half of PSP sufferers experienced symptom onset prior to age 10 has important treatment implications, suggesting that the enhancement of public awareness of PSP may be especially important in the parents of young children.
PSP behaviors may be associated with different disorders including OCD, Prader-Willi syndrome, BDD, and delusions (347). BDD is characterized by a distortion of body image resulting in a distressing and pathologic attention to body image (348). PSP has been found to co-occur with BDD (344,348,349). In PSP secondary to BDD, picking behaviors are aimed at improving the skin’s appearance and mild or nonexistent imperfections are targeted (348,350). Grant et al. (348) studied the clinical characteristics and prevalence of PSP in a sample of 176 individuals with BDD: 44.9% of participants met criteria for lifetime PSP secondary to BDD, and 36.9% met criteria for current PSP secondary to BDD.
OCD, ICD, and PSP
The repetitive nature of PSP shares similarities with compulsive acts seen in disorders such as OCD. Frequencies of co-occurring OCD are significantly higher among individuals with PSP (6% to 52%) in comparison to the general population (1% to 3%) (347) although differences may exist between the disorders. A study conducted by Arzeno Ferrão et al. (351) using the SCID-IV assessed individuals with BFRBs (i.e., PSP and trichotillomania) and individuals with OCD, in order to assess any significant between-group differences in impulsive/compulsive characteristics. In comparison to individuals with OCD, individuals with BRFBs displayed the following differences: (a) a more rapid impulse onset and a decreased ability to delay impulses; (b) more immediate engagement in impulsive behaviors subsequent to impulses/desires and decreased time contemplating behaviors prior to initiation; (c) an “ego-syntonic” or nonaversive/pleasurable experience during engagement in behaviors; (d) a greater sensation of guilt subsequent to engaging in behaviors; (e) fewer behavior-associated ritualistic behaviors; and (f) fewer delusions of persecution (351).
Neurochemistry
Frecska and Arato (352) compared opioid receptor sensitivity—as assessed via fentanyl-induced prolactin response— in individuals with trichotillomania in comparison to individuals with PSP. An elevated prolactin level response was found in individuals with PSP (vs. trichotillomania and healthy controls) suggesting that dysregulation of the endogenous opioid system may play an important role in the pathophysiology of PSP. Researchers have hypothesized that PSP behaviors may be subjectively perceived as more self-injurious than are trichotillomania behaviors (352). As such, this finding is consistent with data suggesting an up-regulation of opioid receptors in individuals with SIBs.
As with trichotillomania, some—but not all— individuals with PSP may be successfully treated with SSRIs. One open-label trial of escitalopram reported significant reductions in PSP symptoms (353). Of the 19 individuals who completed the 18-week open-label trial, pre- and posttreatment data indicated a significant reduction in PSP symptoms: 11 (57.9%) individuals fully responded to treatment, 5 (26.3%) individuals partially responded, and 3 (15.8%) individuals experienced no abatement of PSP symptoms (i.e., were nonresponsive). A double-blind study reported that while PSP symptoms at first decreased in placebo conditions, symptoms returned to baseline levels after 6 weeks. In contrast, fluoxetine administration reduced over 60% of symptoms after 6 weeks. However, mild skin-picking urges and occasional skin-picking behaviors remained (354).
Glutamatergic agents have also shown early promise in the treatment of PSP. Grant et al. (355) tested the efficacy of lamotrigine, an anticonvulsant glutamatergic agent also used as a mood stabilizer, in treating PSP symptoms in a sample of 24 individuals and reported a subsequent improvement in 66% of participants. Several case reports also suggest that riluzole augmentation of fluoxetine (356) and N-acetyl cysteine (356,357) are effective in alleviating PSP symptoms. Together, these preliminary data suggest the need for more investigation of glutamate systems in the pathophysiology and treatment of PSP.
Population Genetics
Recent research suggests genetic contributions to the development of PSP. PSP was endorsed by 1.2% of twins from the Twins UK adult twin registry (358). Significantly higher concordance rates of monozygotic versus dizygotic twin pairs indicated a strong genetic influence on skin picking. Moreover, the authors reported that genetic factors accounted for slightly over 40% of the variance in skin picking.
Conclusion
Data suggest that PSP may be associated with increased rates of suicide and other negative sequelae. However, the neurobiology of this disorder is incompletely understood. Given the chronic nature of PSP, further research into appropriate treatment interventions is warranted.
INTERMITTENT EXPLOSIVE DISORDER
Although disorders of impulsive aggression have been included in early editions of the DSM, IED was introduced in the DSM-III. IED is defined as a failure to inhibit aggressive impulses that are out of proportion to any precipitating stressor (internal or external), resulting in destruction of property or serious physical assault in the DSM-IV-TR (20). A diagnosis of IED is given only if the aggressive behavior cannot be explained by another mental disorder, such as a personality disorder or manic episode, or by substance use (20). Under earlier DSM-III criteria, a diagnosis of IED should not have been given if the patient also met criteria for generalized aggression or impulsivity. As such, prevalence estimates based upon older DSM-III criteria probably underestimate the prevalence of IED (359,360). Although this criterion was dropped from the DSM-IV, other uncertainties (e.g., time course, thresholds, and indices of severity for disease onset/symptom presentation) remain.
Epidemiology
Only a few epidemiologic studies have examined the prevalence and correlates of IED.
Data from a large national epidemiology survey in the United States, the National Comorbidity Survey Replication, indicate that as many as 7.3% of adults (~11.5 to 16 million Americans) may meet lifetime criteria for IED, and 3.9% may meet criteria for 12-month IED (361). In a different prevalence study assessing IED based on DSM-IV criteria in a community sample, Coccaro et al. (362) estimated that up to 1.4 million Americans may meet current IED criteria and as many as 10 million may meet lifetime criteria.
Neurocircuitry
The neuroanatomical literature on human aggressive behaviors has focused primarily on brain areas implicated in fear response such as the amygdala and the PFC. Current research suggests that neural circuitry connecting the OFC, vmPFC, dlPFC, ACC, and amygdala may mediate emotion regulation and impulse control, with dysregulated function within this circuit associated with more impulsive aggressive behaviors and deficits in general emotion regulation (363).
Coccaro et al. (364) performed fMRI scans on 10 individuals with IED and 10 controls during a gender-decision task of emotional faces. There was no significant difference in fMRI gender-task performance accuracy or postscan emotion recognition task accuracy for IED versus control participants. Analyses of the fMRI data found a significant difference between the two groups for degree of amygdala and OFC activation: In response to angry faces, IED individuals displayed significantly greater amygdalar activation and significantly reduced OFC activation, and prior levels of aggressive behavior were associated with greater amygdalar activity. Whereas control subjects displayed an inverse relationship between amygdala and OFC activations during presentation of emotional faces, as was consistent with previous research of fear processing, no such relationship was found for individuals with IED. These data suggest a dysregulation of inhibitory “top–down” OFC processes in individuals with IED.
Neurochemistry
Neurochemical research on human aggression has generally focused on corticotropin-releasing factor, NE, and 5-HT. Subjects with IED have been reported to have a dysregulation of the 5-HT system, and pharmacotherapy targeting the 5-HT system has been found to reduce aggressive and impulsive behaviors (reviewed in Ref. (365)). A reduced CSF concentration of 5-HIAA has been reported in individuals with IED, with lowered levels of 5-HIAA associated with more frequent or severe impulsive aggression (366). A study of aggressive behaviors among individuals with a personality disorder found an inverse relationship between platelet 5-HT concentration and a history of lifetime aggression (366). No significant relationship between platelet 5-HT concentration and impulsivity was reported.
There have been two ligand-based studies suggesting alterations in 5-HT among individuals with IED. Frankle et al. (367) reported decreased availability of the 5-HT transporter within the anterior cingulate. More recently, Rosell et al. (368) reported increased availability of the 5-HT2A receptor within the OFC. Overall, neurochemical data suggest a complex relationship between 5-HT and aggressive behavior, and preliminary investigations suggest efficacy of SSRIs in treating IED symptoms (reviewed in Ref. (365)).
Conclusion
Although many uncertainties regarding IED’s diagnostic criteria remain, recent studies have shed some light on its underlying neurobiology. These include potential dysregulation of inhibitory “top–down” OFC processes and alteration in the serotonergic system. The role other systems (e.g., ventral striatal activity, opioidergic, glutaminergic) may play in IED warrant future investigation.
CONCLUSION
Research on the neurobiology of behavioral addictions has increased in recent years, particularly in PG. Existing research suggests that ICDs share multiple features with SUDs and may be considered behavioral addictions, although alternate conceptualizations also warrant consideration. Additional research is needed to determine how specific ICDs are related to one another and to specific SUDs and how an improved understanding of the biologies of these disorders may be translated into improved prevention and treatment strategies.
REFERENCES
1.Potenza MN. Should addictive disorders include non-substance-related conditions? Addiction 2006;101: 165–174.
2.Maddux JF, Desmond DP. Addiction or dependence? Addiction 2000;95:661–665.
3.Franklin, TR, et al. Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. Neuropsychopharmacology 2007;32(11):2301–2309.
4.O’Brien CP, Volkow N, Li TK. What’s in a word? Addiction versus dependence in DSM-5. Am J Psychiatry 2006;163:764–765.
5.O’Brien C. Addiction and dependence in DSM-5. Addiction 2011;106(5):866–867.
6.Holden C. ‘Behavioral’ addictions: do they exist? Science 2001;294:980–982.
7.Holden C. Behavioral addictions debut in proposed DSM-5. Science 2010;327(5968):935.
8.Volkow ND, O’Brien CP. Issues for DSM-5: should obesity be included as a brain disorder? Am J Psychiatry 2007;164:708–710.
9.Fong TW, Reid RC, Parhami I. Behavioral addictions: where to draw the lines? Psychiatr Clin North Am 2012;35(2):279–296.
10.Potenza MN. Should addictive disorders include non-substance-related conditions? In: Saunders JB, et al., eds. Diagnostic issues in substance use disorders: refining the research agenda for DSM-5. Washington, DC: American Psychiatric Press, Inc., 2007:251–268.
11.American Psychiatric Association. Proposed Revisions—Substance Use and Addictive Disorders. 2012 [cited 2012 Oct 26]; Available from: http://www.dsm5.org/proposedrevision/pages/substanceuseandaddictivedisorders.aspx
12.American Psychiatric Association. Recent Updates to Proposed Revisions for DSM-5. 2012 [cited 2013 Jan 7]; Available from: http://www.dsm5.org/Pages/RecentUpdates.aspx
13.Shaffer HJ. Strange bedfellows: a critical view of pathological gambling and addiction. Addiction 1999;94:1675–1678.
14.Wareham JD, Potenza MN. Pathological gambling and substance use disorders. Am J Drug Alcohol Abuse 2010;36(5):242–247.
15.Chambers R, Bickel WK, Potenza MN. A scale-free systems theory of motivation and addiction. Neurosci Biobehav Rev 2007;31:1017–1045.
16.Redish AD, Jensen S, Johnson A. A unified framework for addiction: vulnerabilities in the decision process. Behav Brain Sci 2008;31(4):415–437.
17.Goldstein RZ, Alia-Klein N, Tomasi D, et al. Is decreased prefrontal cortical sensitivity to monetary reward associated with impaired motivation and self-control in cocaine addiction? Am J Psychiatry2007;164:43–51.
18.Grant JE, Potenza MN. Overview of the impulse control disorders not elsewhere classified and limitations of knowledge. In: Grant JE, Potenza MN, eds. The Oxford handbook of impulse control disorders. New York: Oxford University Press, 2012:3–10.
19.Hollander E, Kim S, Zohar J. OCSDs in the forthcoming DSM-5. CNS Spectr 2007;12:320–323.
20.American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed.–test revision. Washington, DC: American Psychiatric Press, Inc., 2000.
20a.Ziauddeen H, et al. Obesity and the brain: how convincing is the addiction model? Nat Rev Neurosci 2012;13(4):279–286.
20b.Avena NM, et al. Tossing the baby out with the bathwater after a brief rinse? The potential downside of dismissing food addiction based on limited data. Nat Rev Neurosci2012;13(7):514.
21.Frascella J, et al. Shared brain vulnerabilities open the way for nonsubstance addictions: carving addiction at a new joint? Ann N Y Acad Sci 2010;1187(1):294–315.
22.Grant JE, et al. Introduction to behavioral addictions. Am J Drug Alcohol Abuse 2010;36(5):233–241.
23.Grant JE, Odlaug BL, Potenza MN. Addicted to hair pulling? How an alternate model of trichotillomania may improve treatment outcome. Harv Rev Psychiatry 2007;15:80–85.
24.Slutske WS. Natural recovery and treatment-seeking in pathological gambling: results of two national surveys. Am J Psychiatry 2006;163:297–302.
25.el-Guebaly N, et al. Compulsive features in behavioural addictions: the case of pathological gambling. Addiction 2012;107(10):1726–1734.
26.Grant BF, Odlaug BL, Potenza MN. Pathological gambling: clinical characteristics and treatment. In: Fiellin D, et al., eds. Principles of addiction medicine. Philadelphia, PA: Lippincott Williams & Wilkins, 2009:231–253.
27.LaPlante DA, et al. Stability and progression of disordered gambling: lessons from longitudinal studies. Can J Psychiatry 2008;53:52–60.
28.Potenza MN, Steinberg MA, McLaughlin S, et al. Gender-related differences in the characteristics of problem gamblers using a gambling helpline. Am J Psychiatry 2001;181:1730–1735.
29.Yip SW, et al. Health/functioning characteristics, gambling behaviors, and gambling-related motivations in adolescents stratified by gambling problem severity: findings from a high school survey. Am J Addict 2011;20:495–508.
30.Comings DE, Gade-Andavolu R, Gonzalez N, et al. The additive effect of neurotransmitter genes in pathological gambling. Clin Genet 2001;60:107–116.
31.Desai R, Potenza M. Gender differences in the associations between past-year gambling problem and psychiatric disorders. Soc Psychiatry Psychiatr Epidemiol 2008;43:173–183.
32.Lorains FK, Cowlishaw S, Thomas SA. Prevalence of comorbid disorders in problem and pathological gambling: systematic review and meta-analysis of population surveys. Addiction2011;106(3):490–498.
33.Potenza MN. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos Trans R Soc Lond B Biol Sci 2008;363(1507):3181–3189.
34.Linnet J, et al. Dopamine release in ventral striatum during Iowa Gambling Task performance is associated with increased excitement levels in pathological gambling. Addiction2011;106(2):383–390.
35.Bechara A. Risky business: emotion, decision-making, and addiction. J Gambl Stud 2003;19(1):23–51.
36.Goudriaan AE, et al. Decision making in pathological gambling: a comparison between pathological gamblers, alcohol dependents, persons with Tourette syndrome, and normal controls. Cogn Brain Res2005;23(1):137–151.
37.Goudriaan AE, Oosterlaan J, de Beurs E, et al. Neurocognitive functions in pathological gambling: a comparison with alcohol dependence, Tourette syndrome and normal controls. Addiction 2006;101:534–547.
38.Odlaug BL, et al. A neurocognitive comparison of cognitive flexibility and response inhibition in gamblers with varying degrees of clinical severity. Psychol Med 2011;41:2111–2119.
39.Goudriaan AE, et al. The role of self-reported impulsivity and reward sensitivity versus neurocognitive measures of disinhibition and decision-making in the prediction of relapse in pathological gamblers. Psychol Med 2008;38:41–50.
40.Lawrence A, et al. Problem gamblers share deficits in impulsive decision-making with alcohol-dependent individuals. Addiction 2009;104(6):1006–1015.
41.Andrade L, Petry N. Delay and probability discounting in pathological gamblers with and without a history of substance use problems. Psychopharmacology (Berl) 2012;219(2):491–499.
42.Reynolds B. A review of delay-discounting research with humans: relations to drug use and gambling. Behav Pharmacol 2006;17:651–667.
43.Petry NM. Pathological gamblers, with and without substance use disorders, discount delayed rewards at high rates. J Abnorm Psychol 2001;110:482–487.
44.Petry NM. Discounting of probabilistic rewards is associated with gambling abstinence in treatment-seeking pathological gamblers. J Abnorm Psychol 2012;121(1):151–159.
45.Bickel WK, et al. Congruence of BOLD response across intertemporal choice conditions: fictive and real money gains and losses. J Neurosci 2009;29(27):8839–8846.
46.Miedl SF, Peters J, Büchel C. Altered neural reward representations in pathological gamblers revealed by delay and probability discounting. Arch Gen Psychiatry 2012;69(2):177–186.
47.Lebreton M, et al. An automatic valuation system in the human brain: evidence from functional neuroimaging. Neuron 2009;64(3):431–439.
48.Levy DJ, Glimcher PW. The root of all value: a neural common currency for choice. Curr Opin Neurobiol 2012;22:1027–1038.
49.Clark AM. Reward processing: a global brain phenomenon? J Neurophysiol 2012;109(1):1–4.
50.Knutson B, Fong GW, Bennett SM, et al. A region of medial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI. Neuroimage2003;18:263–272.
51.Hariri AR, et al. Preference for immediate over delayed rewards is associated with magnitude of ventral striatal activity. J Neurosci 2006;26(51):13213–13217.
52.Cardinal RN. Neural systems implicated in delayed and probabilistic reinforcement. Neural Netw 2006;19:1277–1301.
53.Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005;8:170–171.
54.Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005;8(11):1481–1489.
55.Potenza MN, Steinberg MA, Skudlarski P, et al. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2003;60:828–836.
56.Potenza MN, Leung HC, Blumberg HP, et al. An FMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003;160:1990–1994.
57.Balodis IM, et al. Diminished frontostriatal activity during processing of monetary rewards and losses in pathological gambling. Biol Psychiatry 2012;71:749–757.
58.Tanabe J, Thompson L, Claus E, et al. Prefrontal cortex activity is reduced in gambling and nongambling substance users during decision-making. Hum Brain Mapp 2007;28:1276–1286.
59.de Greck M, et al. Decreased neuronal activity in reward circuitry of pathological gamblers during processing of personal relevant stimuli. Hum Brain Mapp 2010;31(11):1802–1812.
60.Joutsa J, et al. Extensive abnormality of brain white matter integrity in pathological gambling. Psychiatry Res 2011;194(3):340–346.
61.Yip SW, et al. Reduced genual corpus callosal white matter integrity in pathological gambling and its relationship to alcohol abuse or dependence. World J Biol Psychiatry 2013;14:129–138.
62.Moeller FG, et al. Reduced anterior corpus callosum white matter integrity is related to increased impulsivity and reduced discriminability in cocaine-dependent subjects: diffusion tensor imaging. Neuropsychopharmacology 2005;30(3):610–617.
63.Moeller FG, et al. Diffusion tensor imaging eigenvalues: preliminary evidence for altered myelin in cocaine dependence. Pyschiatry Res 2007;154:253–258.
64.Pfefferbaum A, Sullivan EV. Disruption of brain white matter microstructure by excessive intracellular and extracellular fluid in alcoholism: evidence from diffusion tensor imaging. Neuropsychopharmacology2004;30(2):423–432.
65.Pfefferbaum A, et al. In vivo detection and functional correlates of white matter microstructural disruption in chronic alcoholism. Alcohol Clin Exp Res 2000;24(8):1214–1221.
66.van Holst RJ, et al. A voxel-based morphometry study comparing problem gamblers, alcohol abusers, and healthy controls. Drug Alcohol Depend 2012;124(1–2):142–148.
67.Linnet J, et al. Inverse association between dopaminergic neurotransmission and Iowa Gambling Task performance in pathological gamblers and healthy controls. Scand J Psychol2011;52(1):28–34.
68.Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 2008;75(1):63–75.
69.Nordin C, Eklundh T. Altered CSF 5-HIAA disposition in pathological male gamblers. CNS Spectr 1999;4:25–33.
70.Ettenberg A, et al. Inactivation of the dorsal raphé nucleus reduces the anxiogenic response of rats running an alley for intravenous cocaine. Pharmacol Biochem Behav 2011;97(4):632–639.
71.de Castro IP, et al. Concurrent positive association between pathological gambling and functional DNA polymorphisms at the MAO-A and the 5-HT transporter genes. Mol Psychiatry2002;7:927–928.
72.Ibanez A, et al. Pathological gambling and DNA polymorphic markers at MAO-A and MAO-B genes. Mol Psychiatry 2000;5(1):105–109.
73.de Castro IP, et al. Genetic contribution to pathological gambling: possible association between a functional DNA polymorphism at the serotonin transporter gene (5-HTT) and affected men. Pharmacogenet Genomics 1999;9(3):397–400.
74.DeCaria CM, Begaz T, Hollander E. Serotonergic and noradrenergic function in pathological gambling. CNS Spectr 1998;3:38–45.
75.Pallanti S, et al. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo. CNS Spectr 2006;11:956–964.
76.Pallanti S, et al. Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan. J Psychopharmacol 2010;24(12):1802–1809.
77.Moss HB, et al. Diplotypes of the human serotonin 1B receptor promoter predict growth hormone responses to sumatriptan in abstinent alcohol-dependent men. Biol Psychiatry2007;61(8):974–978.
78.Patkar AA, et al. Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence. Hum Psychopharmacol 2006;21(6):367–375.
79.Potenza MN, et al. Serotonin 1B receptor imaging in pathological gambling. World J Biol Psychiatry 2013;14:139–145.
80.Hollander E, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000;47(9):813–817.
81.Berlin HA, et al. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry 2013;14:121–128.
82.Fong T, et al. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav 2008;89(3):298–303.
83.Blanco C, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 2002;14(1):9–15.
84.Grant JE, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol 2003;18(4):243–249.
85.Bullock SA, Potenza MN. Pathological gambling: neuropsychopharmacology and treatment. Curr Psychopharmacol 2012;1(1):67–85.
86.Linnet J, et al. Dopamine release in ventral striatum of pathological gamblers losing money. Acta Psychiatr Scand 2010;112:326–333.
87.Joutsa J, et al. Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage 2012;60(4):1992–1999.
88.Boileau I, et al. The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride. Addiction 2013;108:953–963. DOI: 10.1111/add.12066.
89.Clark L, et al. Striatal dopamine D2/D3 receptor binding in pathological gambling is correlated with mood-related impulsivity. Neuroimage 2012;63(1):40–46.
90.Zack M, Poulos CX. A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neuropsychopharmacology 2007;32(8):1678–1686.
91.Zack M, Poulos CX. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology 2004;29(1):195–207.
92.Weintraub D, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67(5):589–595.
93.Voon V, et al. Dopamine agonists and risk: impulse control disorders in Parkinson’s disease. Brain 2011;134(5):1438–1446.
94.Ambermoon P, et al. Impulse control disorders in patients with Parkinson’s disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction2011;106(2):283–293.
95.Tremblay A-M, et al. Haloperidol modifies instrumental aspects of slot machine gambling in pathological gamblers and healthy controls. Addict Biol 2011;16(3):467–484.
96.Bergh C, et al. Altered dopamine function in pathological gambling. Psychol Med 1997;27(2):473–475.
97.Nordin C, Sjodin I. CSF monoamine patterns in pathological gamblers and healthy controls. J Psychiatr Res 2006;40(5):454–459.
98.Roy A, et al. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry1988;45(9):849–857.
99.Meyer G, et al. Neuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinology 2004;29(10):1272–1280.
100.Pallanti S, et al. Noradrenergic function in pathological gambling: blunted growth hormone response to clonidine. J Psychopharmacol 2010;24(6):847–853.
101.Kim SW, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001;49(11):914–921.
102.Grant JE, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006;163(2):303–312.
103.Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry2008;69(5):783–789.
104.Grant JE, et al. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry 2011;197(4):330–331.
105.Gupta R, Derevensky J. Familial and social influences on juvenile gambling behavior. J Gambl Stud 1997;13(3):179–192.
106.Eisen SA, et al. Familial influences on gambling 93(9):1375–1384.
107.Tsuang MT, et al. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet 1996;67(5):473–477.
108.Slutske WS, et al. Common genetic vulnerability for pathological gambling and alcohol dependence in men. Arch Gen Psychiatry 2000;57(7):666–673.
109.Slutske WS, et al. A twin study of the association between pathological gambling and antisocial personality disorder. J Abnorm Psychol 2001;110(2):297–308.
110.Slutske WS, et al. Genetic and environmental influences on disordered gambling in men and women. Arch Gen Psychiatry 2010;67(6):624–630.
111.Blanco C, Myers J, Kendler KS. Gambling, disordered gambling and their association with major depression and substance use: a web-based cohort and twin-sibling study. Psychol Med2012;42(3):497–508.
112.Comings DE, et al. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics 1996;6(3):223–234.
113.da Silva S, et al. Dopamine genes and pathological gambling in discordant sib-pairs. J Gambl Stud 2007;23(4):421–433.
114.de Castro IP, et al. Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics 1997;7(5):345–348.
115.Lobo DS, Kennedy JL. Genetic aspects of pathological gambling: a complex disorder with shared genetic vulnerabilities. Addiction 2009;104(9):1454–1465.
116.Lobo DSS, et al. Association of functional variants in the dopamine D2-like receptors with risk for gambling behaviour in healthy Caucasian subjects. Biol Psychol 2010;85(1):33–37.
117.Lim S, et al. Association study on pathological gambling and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in a Korean population. J Gambl Stud 2012;28:481–491.
118.Kreek MJ, et al. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 2005;8(11):1450–1457.
119.Ibáñez A, et al. Genetics of pathological gambling. J Gambl Stud 2003;19(1):11–22.
120.Grant JE, Brewer JA, Potenza MN. The neurobiology of substance and behavioral addictions. CNS Spectr 2006;11(12):924–930.
121.Davis C, Carter JC. Compulsive overeating as an addiction disorder. A review of theory and evidence. Appetite 2009;53(1):1–8.
122.Hudson JI, et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007;61(3):348–358.
123.American Psychiatric Association. DSM-5 proposed revisions will include binge eating disorder and revisions to other eating disorders criteria. 2012 [cited 2013 April 2]; Available from: http://www.dsm5.org/Newsroom/Documents/Eating%20Disorders%20release%20 FINAL%202.05.pdf
124.von Ranson KM, Robinson KE. Who is providing what type of psychotherapy to eating disorder clients? A survey. Int J Eat Disord 2006;39(1):27–34.
125.World Health Organization. Obesity and overweight. 2012 [cited 2012 Jan 29]; Available from: http://www.who.int/mediacentre/factsheets/fs311/en/
126.Ogden CL, et al. Prevalence of obesity in the United States, 2012. National Center for Health Statistics, U.S. Department of Health and Human Services.
127.Joranby L, Pineda KF, Gold MS. Addiction to food and brain reward systems. Sex Addict Compulsivity 2005;12(2–3):201–217.
128.Grilo CM, White MA, Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord 2009;42(3):228–234.
129.Yip S, et al. An exploratory study of clinical measures associated with subsyndromal pathological gambling in patients with binge eating disorder. J Gambl Stud 2011;27:257–270.
130.Bean MK, Stewart K, Olbrisch ME. Obesity in America: implications for clinical and health psychologists. J Clin Psychol Med Settings 2008;15(3):214–224.
131.Drewnowski A, Darmon N. The economics of obesity: dietary energy density and energy cost. Am J Clin Nutr 2005;82(1):265S–273S.
132.Davis CA, et al. Dopamine for “wanting” and opioids for “liking”: a comparison of obese adults with and without binge eating. Obesity 2009;17(6):1220–1225.
133.Balodis IM, et al. Monetary reward processing in obese individuals with and without binge eating disorder. Biol Psychiatry 2013;73:877–886.
134.Balodis IM, et al. Divergent neural substrates of inhibitory control in binge eating disorder relative to other manifestations of obesity. Obesity 2013;21:367–377.
135.Swanson LW. Cerebral hemisphere regulation of motivated behavior. Brain Res 2000;886(1–2):113–164.
136.Enriori PJ, et al. Leptin resistance and obesity. Obesity 2006;14(Suppl 5):254S–258S.
137.Trinko R, et al. Neural mechanisms underlying obesity and drug addiction. Physiol Behav 2007;91(5):499–505.
138.Kiefer F, et al. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism. J Psychiatr Res 2005;39(5):545–551.
139.Halaas JL, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269(5223):543–546.
140.Unger RH, et al. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010;1801(3):209–214.
141.Berman SM, et al. Effects of leptin deficiency and replacement on cerebellar response to food-related cues. Cerebellum 2013;12:59–67.
142.Farooqi IS, et al. Leptin regulates striatal regions and human eating behavior. Science 2007;317(5843):1355.
143.Small DM, et al. Changes in brain activity related to eating chocolate: from pleasure to aversion. Brain 2001;124(Pt 9):1720–1733.
144.Rothemund Y, et al. Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals. Neuroimage 2007;37(2):410–421.
145.Jastreboff AM, et al. Neural correlates of stress- and food cue-induced food craving in obesity: association with insulin levels. Diabetes Care 2013;36:394–402.
146.Kaye WH, Frank GK, McConaha C. Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology 1999;21(4):503–506.
147.Wagner A, et al. Altered reward processing in women recovered from anorexia nervosa. Am J Psychiatry 2007;164(12):1842–1849.
148.Cowdrey FA, et al. Increased neural processing of rewarding and aversive food stimuli in recovered anorexia nervosa. Biol Psychiatry 2011;70(8):736–743.
149.Billes SK, Simonds SE, Cowley MA. Leptin reduces food intake via a dopamine D2 receptor-dependent mechanism. Mol Metab 2012;1:86–93.
150.Volkow ND, et al. Imaging dopamine’s role in drug abuse and addiction. Neuropharmacology 2009;56(Suppl 1):3–8.
151.Volkow ND, et al. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 2007;64(11):1575–1579.
152.Wang G-J, et al. Brain dopamine and obesity. Lancet 2001;357(9253):354–357.
153.Wang GJ, et al. Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review. J Addict Dis 2004;23(3):39–53.
154.Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 2010;13(5):635–641.
155.Figlewicz DP, et al. Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res 2003;964(1):107–115.
156.Hommel JD, et al. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 2006;51(6):801–810.
157.Elmquist JK, et al. Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol 1998;395(4):535–547.
158.Shanley LJ, Irving AJ, Harvey J. Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosci 2001;21:RC186.
159.Fulton S, Woodside B, Shizgal P. Modulation of brain reward circuitry by leptin. Science 2000;287(5450):125–128.
160.Kotz C, et al. Brain orexin promotes obesity resistance. Ann N Y Acad Sci 2012;1264(1):72–86.
161.Sakurai T, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92(4):573–585.
162.Chemelli RM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98(4):437–451.
163.Sharf R, et al. Orexin signaling via the orexin 1 receptor mediates operant responding for food reinforcement. Biol Psychiatry 2010;67(8):753–760.
164.Boutrel B, et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci U S A 2005;102(52):19168–19173.
165.Georgescu D, et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 2003;23(8):3106–3111.
166.Lawrence AJ, et al. The orexin system regulates alcohol-seeking in rats. Br J Pharmacol 2006;148(6):752–759.
167.Smith RJ, Aston-Jones G. Orexin/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur J Neurosci 2012;35(5):798–804.
168.Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005;437(7058):556–559.
169.James MH, et al. Orexin-1 receptor signalling within the ventral tegmental area, but not the paraventricular thalamus, is critical to regulating cue-induced reinstatement of cocaine-seeking. Int J Neuropsychopharmacol 2011;14(5):684.
170.Narita M, et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci 2006;26(2):398–405.
171.Vittoz NM, Berridge CW. Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: involvement of the ventral tegmental area. Neuropsychopharmacology2006;31(2):384–395.
172.Dickson SL, et al. The role of the central ghrelin system in reward from food and chemical drugs. Mol Cell Endocrinol 2011;340(1):80–87.
173.Cummings DE, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50(8):1714–1719.
174.Tschop M, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50(4):707–709.
175.Overduin J, et al. Ghrelin increases the motivation to eat, but does not alter food palatability. Am J Physiol Regul Integr Comp Physiol 2012;303(3):R259–R269.
176.Abizaid A, et al. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest 2006;116(12):3229.
177.Skibicka KP, et al. Ghrelin directly targets the ventral tegmental area to increase food motivation. Neuroscience 2011;180:129–137.
178.Abizaid A, et al. Reduced locomotor responses to cocaine in ghrelin-deficient mice. Neuroscience 2011;192(0):500–506.
179.Nicola SM, et al. Nucleus accumbens dopamine release is necessary and sufficient to promote the behavioral response to reward-predictive cues. Neuroscience 2005;135(4):1025–1033.
180.Kelley AE, et al. Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 2002;76(3):365–377.
181.Kelley AE, Bless EP, Swanson CJ. Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats. J Pharmacol Exp Ther1996;278(3):1499–1507.
182.Taha SA, Fields HL. Encoding of palatability and appetitive behaviors by distinct neuronal populations in the nucleus accumbens. J Neurosci 2005;25(5):1193–1202.
183.Kelley AE, et al. Corticostriatal-hypothalamic circuitry and food motivation: integration of energy, action and reward. Physiol Behav 2005;86(5):773–795.
184.Cota D, et al. Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity. J Endocrinol Invest 2003;26(10):1041–1044.
185.Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8(5):585–589.
186.Monteleone P, et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology2005;30(6):1216–1221.
187.Di Marzo V, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410(6830):822–825.
188.Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001;22(11):565–572.
189.Mahler SV, Smith KS, Berridge KC. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances ‘liking’ of a sweet reward. Neuropsychopharmacology2007;32(11):2267–2278.
190.Yoshida R, et al. Endocannabinoids selectively enhance sweet taste. Proc Natl Acad Sci 2010;107(2):935–939.
191.Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009;205(1):171–174.
192.Lazary J, et al. Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists. Trends Pharmacol Sci 2011;32(5):270–280.
193.Meye FJ, et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry 2012;18(12):1294–1301.
194.Rosen HJ, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002;58(2):198–208.
195.Mendez MF, Licht EA, Shapira JS. Changes in dietary or eating behavior in frontotemporal dementia versus Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2008;23(3):280–285.
196.Woolley JD, et al. Binge eating is associated with right orbitofrontal-insular-striatal atrophy in frontotemporal dementia. Neurology 2007;69(14):1424–1433.
197.DelParigi A, et al. Successful dieters have increased neural activity in cortical areas involved in the control of behavior. Int J Obes (Lond) 2007;31(3):440–448.
198.McCaffery JM, et al. Differential functional magnetic resonance imaging response to food pictures in successful weight-loss maintainers relative to normal-weight and obese controls. Am J Clin Nutr2009;90(4):928–934.
199.Uher R, et al. Effect of left prefrontal repetitive transcranial magnetic stimulation on food craving. Biol Psychiatry 2005;58(10):840–842.
200.Barr MS, et al. Repetitive transcranial magnetic stimulation and drug addiction. Int Rev Psychiatry 2011;23(5):454–466.
201.Davis C, et al. Decision-making deficits and overeating: a risk model for obesity. Obes Res 2004;12:929–935.
202.Brogan A, et al. Impaired decision making among morbidly obese adults. J Psychosom Res 2011;70(2):189–196.
203.Danner UN, et al. Decision-making impairments in women with binge eating disorder in comparison with obese and normal weight women. Eur Eat Disord Rev 2012;20(1):e56–e62.
204.Tchanturia K, et al. An investigation of decision making in anorexia nervosa using the Iowa Gambling Task and skin conductance measurements. J Int Neuropsychol Soc2007;13(4):635–641.
205.Liao PC, et al. An examination of decision making in bulimia nervosa. J Clin Exp Neuropsychol 2009;31(4):455–461.
206.Brand M, et al. Decision-making impairments in patients with pathological gambling. Psychiatry Res 2005;133(1):91–99.
207.Brand M, et al. Cognitive estimation and affective judgments in alcoholic Korsakoff patients. J Clin Exp Neuropsychol 2003;25(3):324–334.
208.Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998;44(9):851–864.
209.Halford JC, et al. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007;67(1):27–55.
210.Heisler LK, et al. Activation of central melanocortin pathways by fenfluramine. Science 2002;297(5581):609–611.
211.Smith BK, York DA, Bray GA. Activation of hypothalamic serotonin receptors reduced intake of dietary fat and protein but not carbohydrate. Am J Physiol 1999;277(3 Pt 2):R802–R811.
212.Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity and depression. Obes Res 1995;3(S4):477S–480S.
213.McElroy SL, et al. Pharmacological management of binge eating disorder: current and emerging treatment options. Ther Clin Risk Manag 2012;8:219.
214.Reas DL, Grilo CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring) 2008;16(9):2024–2038.
215.Leombruni P, et al. A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters. Hum Psychopharmacol 2006;21(3):181–188.
216.Leombruni P, et al. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. Prog Neuropsychopharmacol Biol Psychiatry2008;32(6):1599–1605.
217.Guerdjikova AI, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol 2008;23(1):1–11.
218.Devlin MJ, et al. Cognitive behavioral therapy and fluoxetine for binge eating disorder: two-year follow-up. Obesity (Silver Spring) 2007;15(7):1702–1709.
219.Coleman E, et al. Nefazodone and the treatment of nonparaphilic compulsive sexual 61(4):282–284.
220.Schaffer SD, Zimmerman ML. The sexual addict: a challenge for the primary care provider. Nurse Pract 1990;15(6):25–26, 28, 33.
221.Mick TM, Hollander E. Impulsive-compulsive sexual behavior. CNS Spectr 2006;11(12):944–955.
222.Kafka MP, Prentky RA. Preliminary observations of DSM-III-R axis I comorbidity in men with paraphilias and paraphilia-related disorders. J Clin Psychiatry 1994;55(11):481–487.
223.Grant JE, Steinberg MA. Compulsive sexual behavior and pathological gambling. Sex Addict Compulsivity 2005;12(2–3):235–244.
224.Kor A, et al. Should hypersexual disorder be classified as an addiction? Sex Addict Compulsivity 2013;20(1–2).
225.Coleman E. Is your patient suffering from compulsive sexual behavior? Psychiatric Ann 1992;22:320–325.
226.Kafka MP. Hypersexual disorder: a proposed diagnosis for DSM-5. Arch Sex Behav 2010;39(2):377–400.
227.Kinsey AC, Pomeroy WB, Martin CE. Sexual behavior in the human male. Am J Public Health 2003;93:894–898.
228.Grant JE, et al. Prevalence of impulse control disorders in adult psychiatric inpatients. Am J Psychiatry 2005;162:2184–2188.
229.Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007;64(8):1089–1096.
230.Chou CL, et al. Persistent Klüver-Bucy syndrome after bilateral temporal lobe infarction. Acta Neurol Taiwan 2008;17(3):199–202.
231.Miner MH, et al. Preliminary investigation of the impulsive and neuroanatomical characteristics of compulsive sexual behavior. Psychiatry Res 2009;174(2):146–151.
232.Fong TW, De La Garza R II, Newton TF. A case report of topiramate in the treatment of nonparaphilic sexual addiction. J Clin Psychopharmacol 2005;25(5):512–514.
233.Hirschfeld RM. Long-term side effects of SSRIs: sexual dysfunction and weight gain. J Clin Psychiatry 2003;64(Suppl 18):20–24.
234.Wainberg ML, et al. A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. J Clin Psychiatry 2006;67(12):1968–1973.
235.Kafka MP, Hennen J. Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. J Clin Psychiatry2000;61(9):664–670.
236.Sathe RS, et al. Naltrexone-induced augmentation of sexual response in men. Arch Med Res 2001;32(3):221–226.
237.Dannon PN. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin Neuropharmacol 2003;26(1):1–4.
238.Grant J, Kim SW. A case of kleptomania and compulsive sexual behavior treated with naltrexone. Ann Clin Psychiatry 2001;13(4):229–231.
239.Ryback RS. Naltrexone in the treatment of adolescent sexual offenders. J Clin Psychiatry 2004;65(7):982–986.
240.Driver-Dunckley ED, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007;30(5):249–255.
241.Leeman RF, Potenza MN. Impulse control disorders in Parkinson’s disease: clinical characteristics and implications. Neuropsychiatry (London) 2011;1(2):133–147.
242.Ko CH, et al. The association between Internet addiction and psychiatric disorder: a review of the literature. Eur Psychiatry 2012;27(1):1–8.
243.Sanders CE, et al. The relationship of Internet use to depression and social isolation among adolescents. Adolescence 2000;35:237–242.
244.Willoughby T. A short-term longitudinal study of Internet and computer game use by adolescent boys and girls: prevalence, frequency of use, and psychosocial predictors. Dev Psychol2008;44(1):195–204.
245.Chen WJ, Boase J, Wellman B. The global villagers: comparing Internet users and uses around the world. In: Wellman B, Haythornthwaite C, eds. The Internet in everyday life. Oxford, UK: Blackwell, 2002:74–113.
246.Anderson KJ. Internet use among college students: an exploratory study. J Am Coll Health 2000;50(1):21–26.
247.Liu TC, et al. Problematic Internet use and health in adolescents: data from a high school survey in Connecticut. J Clin Psychiatry 2011;72(6):836–845.
248.Milani L, Osualdella D, Di Blasio P. Quality of interpersonal relationships and problematic Internet use in adolescence. Cyberpsychol Behav 2009;12(6):681–684.
249.Shapira NA, et al. Psychiatric features of individuals with problematic Internet use. J Affect Disord 2000;57(1–3):267–272.
250.Shaw M, Black DW. Internet addiction. CNS Drugs 2008;22(5):353–365.
251.Ko CH, et al. Proposed diagnostic criteria and the screening and diagnostic tool of Internet addiction in college students. Compr Psychiatry 2009;50:378–384.
252.Tao R, et al. Proposed diagnostic criteria for internet addiction. Addiction 2010;105(3):556–564.
253.Dowling NA, Quirk KL. Screening for Internet dependence: do the proposed diagnostic criteria differentiate normal from dependent Internet use? Cyberpsychol Behav 2009;12(1):21–27.
254.Young KS. Internet addiction: symptoms, evaluation and treatment. In: VandeCreek L, Jackson T, eds. Innovations in clinical practice: a source book. Sarasota, FL: Professional Resource Press, 1999:19–31.
255.Bernardi S, Pallanti S. Internet addiction: a descriptive clinical study focusing on comorbidities and dissociative symptoms. Compr Psychiatry 2009;50(6):510–516.
256.Han DH, et al. The effect of methylphenidate on Internet video game play in children with attention-deficit/hyperactivity disorder. Compr Psychiatry 2009;50(3):251–256.
257.Widyanto L, McMurran M. The psychometric properties of the internet addiction test. Cyberpsychol Behav 2004;7(4):443–450.
258.Yau YHC, et al. Are Internet use and video-game-playing addictive behaviors? Biological, clinical and public health implications for youths and adults. Minerva Psichiatr 2012;53:153–170.
259.Bai YM, Lin CC, Chen JY. Internet addiction disorder among clients of a virtual clinic. Psychiatr Serv 2001;52(10):1397.
260.Lam LT, et al. Factors associated with Internet addiction among adolescents. Cyberpsychol Behav 2009;12(5):551–555.
261.Yen J-Y, et al. The association between harmful alcohol use and Internet addiction among college students: comparison of personality. Psychiatry Clin Neurosci 2009;63(2):218–224.
262.Mazhari S. Association between problematic Internet use and impulse control disorders among Iranian university students. Cyberpsychol Behav Soc Netw 2012;15(5):270–273.
263.Dowling NA, Brown M. Commonalities in the psychological factors associated with problem gambling and Internet dependence. Cyberpsychol Behav Soc Netw 2010;13(4):437–441.
264.Liu J, et al. Increased regional homogeneity in internet addiction disorder: a resting state functional magnetic resonance imaging study. Chin Med J (Engl) 2010;123(14):1904–1908.
265.Dong G, et al. Impaired inhibitory control in ‘internet addiction disorder’: a functional magnetic resonance imaging study. Psychiatry Res 2012;203(2–3):153–158.
266.Dong G, Huang J, Du X. Enhanced reward sensitivity and decreased loss sensitivity in Internet addicts: an fMRI study during a guessing task. J Psychiatr Res 2011;45(11):1525–1529.
267.Zhou Y, et al. Grey matter abnormalities in Internet addiction: a voxel-based morphometry study. Eur J Radiol 2011;79:92–95.
268.Yuan K, et al. Microstructure abnormalities in adolescents with Internet addiction disorder. PLoS One 2011;6(6):e20708.
269.Lin F, et al. Abnormal white matter integrity in adolescents with Internet addiction disorder: a tract-based spatial statistics study. PLoS One 2012;7(1):e30253.
270.Hou H, et al. Reduced striatal dopamine transporters in people with Internet addiction disorder. J Biomed Biotechnol 2012;2012:Article ID 854524.
271.Kim SH, et al. Reduced striatal dopamine D2 receptors in people with Internet addiction. Neuroreport 2011;22(8):407–411.
272.Lee YS, et al. Depression like characteristics of 5HTTLPR polymorphism and temperament in excessive internet users. J Affect Disord 2008;1–2:165–169.
273.Montag C, et al. The role of the CHRNA4 gene in Internet addiction: a case–control study. J Addict Med 2012;6(3):191–195.
274.Yen J-Y, et al. The comorbid psychiatric symptoms of Internet addiction: attention deficit and hyperactivity disorder (ADHD), depression, social phobia, and hostility. J Adolesc Health2007;41(1):93–98.
275.Bakken IJ, et al. Internet addiction among Norwegian adults: a stratified probability sample study. Scand J Psychol 2009;50(2):121–127.
276.Morahan-Martin JM, Schumacher P. Incidence and correlates of pathological Internet use. Comput Human Behav 2000;16:13–19.
277.Mottram AJ, Fleming MJ. Extraversion, impulsivity, and online group membership as predictors of problematic Internet use. Cyberpsychol Behav 2009;12(3):319–321.
278.Pew Research Center. Who’s online: Internet user demographics (Adults). 2011.
279.Sim T, et al. A conceptual review of research of pathological use ofissue computers, video games, and the Internet. Int J Ment Health Addict 2012;10:748–769.
280.Griffiths MD. The educational benefits of videogames. Educ Health 2002;20:47–51.
281.Sussman S, Lisha N, Griffiths M. Prevalence of the addictions: a problem of the majority or the minority? Eval Health Prof 2011;34(1):3–56.
282.Hwang SW. Fifth hour game playing leads to death,‘in Chung Ang Daily. Dae Gu, Korea, 2005.
283.Payne JW. Caught on the Web, in Washington Post 2006.
284.Tejeiro Salguero RA, Bersabé Morán RM. Measuring problem video game playing in adolescents. Addiction 2002;97(12):1601–1606.
285.Gentile DA, et al. Pathological video game use among youths: a two-year longitudinal study. Pediatrics 2011;127(2):e319–e329.
286.Desai RA, et al. Video-gaming among high school students: health correlates, gender differences, and problematic gaming. Pediatrics 2010;126(6):1414–1424.
287.Ream GL, Elliott LC, Dunlap E. Patterns of and motivations for concurrent use of video games and substances. Int J Environ Res Public Health 2011;8(10):3999–4012.
288.Porter G, et al. Recognizing problem video game use. Aust N Z J Psychiatry 2010;44(2):120–128.
289.Kühn S, et al. The neural basis of video gaming. Transl Psychiatry 2011;1:e53.
290.Han DH, et al. Brain activity and desire for Internet video game play. Compr Psychiatry 2011;51:88–95.
291.Ko C-H, et al. Brain activities associated with gaming urge of online gaming addiction. J Psychiatr Res 2009;43(7):739–747.
292.Han DH, et al. Changes in cue-induced, prefrontal cortex activity with video-game play. Cyberpsychol Behav Soc Netw 2010;13(6):655–661.
293.Ko CH, et al. Brain correlates of craving for online gaming under cue exposure in subjects with Internet gaming addiction and in remitted subjects. Addict Biol 2013;18:559–569.
294.Koepp MJ, et al. Evidence for striatal dopamine release during a video game. Nature 1998;393(6682):266–268.
295.Weinstein AM. Computer and video game addiction-a comparison between game users and non-game users. Am J Drug Alcohol Abuse 2010;36:268–276.
296.Farde L, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry1992;49(7):538–544.
297.Volkow ND, et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994;16(4):255–262.
298.Han DH, Hwang JW, Renshaw PF. Bupropion sustained release treatment decreases craving for video games and cue-induced brain activity in patients with Internet video game addiction. Exp Clin Psychopharmacol 2010;18(4):297–304.
299.Han DH, et al. Dopamine genes and reward dependence in adolescents with excessive internet video game play. J Addict Med 2007;1(3):133–138.
300.Kraepelin E. Psychiatrie, 8th ed. Leipzig, Germany: Barth, 1915.
301.Lejoyeux M, et al. Phenomenology and psychopathology of uncontrolled buying. Am J Psychiatry 1996;153(12):1524–1529.
302.Raab G, et al. A neurological study of compulsive buying behaviour. J Consum Policy 2011;34(4):401–413.
303.Knutson B, et al. Neural predictors of purchases. Neuron 2007;53(1):147–156.
304.Koran LM, et al. Citalopram treatment of compulsive shopping: an open-label study. J Clin Psychiatry 2002;63(8):704–708.
305.Black DW, et al. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry 2000;12(4):205–211.
306.Koran LM, et al. Escitalopram for compulsive buying disorder: a double-blind discontinuation study. J Clin Psychopharmacol 2007;27(2):225–227.
307.Kim SW. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry 1998;59(4):159–164.
308.Grant JE. Three cases of compulsive buying treated with naltrexone. Int J Psychiatry Clin Pract 2003;7(3):223–225.
309.Grant JE, Odlaug BL, Kim SW. Kleptomania: clinical characteristics and relationship to substance use disorders. Am J Drug Alcohol Abuse 2010;36(5):291–295.
310.Presta S, et al. Kleptomania: clinical features and comorbidity in an Italian sample. Compr Psychiatry 2002;43(1):7–12.
311.Grant JE. Family history and psychiatric comorbidity in persons with kleptomania. Compr Psychiatry 2003;44(6):437–441.
312.Lejoyeux M, et al. Study of impulse-control disorders among alcohol-dependent patients. J Clin Psychiatry 1999;60(5):302–305.
313.Grant JE, Correia S, Brennan-Krohn T. White matter integrity in kleptomania: a pilot study. Psychiatry Res 2006;147(2–3):233–237.
314.Grant JE, Odlaug BL, Wozniak JR. Neuropsychological functioning in kleptomania. Behav Res Ther 2007;45(7):1663–1670.
315.Aizer A, Lowengrub K, Dannon PN. Kleptomania after head trauma: two case reports and combination treatment strategies. Clin Neuropharmacol 2004;27(5):211–215.
316.Kaplan Y. Epilepsy and kleptomania. Epilepsy Behav 2007;11(3):474–475.
317.Nyffeler T, Regard M. Kleptomania in a patient with a right frontolimbic lesion. Neuropsychiatry Neuropsychol Behav Neurol 2001;14(1):73–76.
318.McElroy SL, et al. Kleptomania: a report of 20 cases. Am J Psychiatry 1991;148(5):652–657.
319.Burstein A. Fluoxetine-lithium treatment for kleptomania. J Clin Psychiatry 1992;53(1):28–29.
320.Koran LM, Aboujaoude EN, Gamel NN. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J Clin Psychiatry 2007;68(3):422–427.
321.Grant JE, Kim SW. Adolescent kleptomania treated with naltrexone—a case report. Eur Child Adolesc Psychiatry 2002;11(2):92–95.
322.Grant JE, Kim SW. An open-label study of naltrexone in the treatment of kleptomania. J Clin Psychiatry 2002;63(4):349–356.
323.Hallopeau H. Alopecie par grattage (trichomanie ou trichotillomanie). Ann Dermatol Syphiligr 1889;10:440–446.
324.Duke DC, et al. Trichotillomania: a current review. Clin Psychol Rev 2010;30(2):181–193.
325.Salaam K, et al. Untreated trichotillomania and trichophagia: surgical emergency in a teenage girl. Psychosomatics 2005;46(4):362–366.
326.Christenson GA, Pyle RL, Mitchell JE. Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry 1991;52:415–417.
327.Christenson GA, Crow SJ. The characterization and treatment of trichotillomania. J Clin Psychiatry 1996;57:42–47.
328.Cohen LJ, et al. Clinical profile, comorbidity, and treatment history in 123 hair pullers: a survey study. J Clin Psychiatry 1995;56(7):319–326.
329.King RA, et al. An epidemiological study of trichotillomania in Israeli adolescents. J Am Acad Child Adolesc Psychiatry 1995;34(9):1212–1215.
330.Vythilingum B, et al. SPECT scans in identical twins with trichotillomania. J Neuropsychiatry Clin Neurosci 2002;14(3):340–342.
331.Rauch SL, et al. Brain activation during implicit sequence learning in individuals with trichotillomania. Psychiatry Res 2007;154(3):233–240.
332.Grachev ID. MRI-based morphometric topographic parcellation of human neocortex in trichotillomania. Psychiatry Clin Neurosci 1997;51:315–321.
333.O’Sullivan RL, et al. Reduced basal ganglia volumes in trichotillomania measured via morphometric magnetic resonance imaging. Biol Psychiatry 1997;42(1):39–45.
334.Stein DJ, et al. Magnetic resonance imaging in women with obsessive–compulsive disorder and trichotillomania. Psychiatry Res 1991;3:177–182.
335.Chamberlain S, et al. Reduced brain white matter integrity in trichotillomania: a diffusion tensor imaging study. Arch Gen Psychiatry 2010;67(9):965–971.
336.Bloch MH, et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry 2007;62(8):839–846.
337.Carrion VG. Naltrexone for the treatment of trichotillomania: a case report. J Clin Psychopharmacol 1995;15(6):444–445.
338.Odlaug BL, Chamberlain SR, Grant JE. Motor inhibition and cognitive flexibility in pathologic skin picking. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:208–211.
339.Bodfish JW, et al. Dyskinetic movement disorder among adults with mental retardation: phenomenology and co-occurrence with stereotypy. Am J Ment Retard 1996;101(2):118–129.
340.Bodfish J, et al. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord 2000;30(3):237–243.
341.Snorrason I, Belleau EL, Woods DW. How related are hair pulling disorder (trichotillomania) and skin picking disorder? A review of evidence for comorbidity, similarities and shared etiology. Clin Psychol Rev 2012;32(7):618–629.
342.Bohne A, et al. Prevalence of body dysmorphic disorder in a German college student sample. Psychiatry Res 2002;109(1):101–104.
343.Hayes SL, Storch EA, Berlanga L. Skin picking behaviors: an examination of the prevalence and severity in a community sample. J Anxiety Disord 2009;23(3):314–319.
344.Keuthen NJ, et al. The prevalence of pathologic skin picking in US adults. Compr Psychiatry 2010;51(2):183–186.
345.Odlaug BL, Grant JE. Childhood-onset pathologic skin picking: clinical characteristics and psychiatric comorbidity. Compr Psychiatry 2007;48(4):388–393.
346.Bohne A, Keuthen N, Wilhelm S. Pathologic hairpulling, skin picking, and nail biting. Ann Clin Psychiatry 2005;17(4):227–232.
347.Grant JE, et al. Skin picking disorder. Am J Psychiatry 2012;169(11):1143–1149.
348.Grant JE, Menard W, Phillips KA. Pathological skin picking in individuals with body dysmorphic disorder. Gen Hosp Psychiatry 2006;28(6):487–493.
349.Grant JE, Odlaug BL, Kim SW. A clinical comparison of pathologic skin picking and obsessive-compulsive disorder. Compr Psychiatry 2010;51(4):347–352.
350.Phillips KA, Taub SL. Skin picking as a symptom of body dysmorphic disorder. Psychopharmacol Bull 1995;31(2):279–288.
351.Arzeno Ferrão Y, et al. Impulsivity and compulsivity in patients with trichotillomania or skin picking compared with patients with obsessive-compulsive disorder. Compr Psychiatry2006;47(4):282–288.
352.Frecska E, Arato M. Opiate sensitivity test in patients with stereotypic movement disorder and trichotillomania. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(5):909–912.
353.Keuthen N, et al. Open-label escitalopram treatment for pathological skin picking. Int Clin Psychopharmacol 2007;22(5):268–274.
354.Bloch MR, et al. Fluoxetine in pathologic skin-picking. Psychosomatics 2001;42(4):314–319.
355.Grant JE, Odlaug BL, Kim SW. Lamotrigine treatment of pathologic skin picking: an open-label study. J Clin Psychiatry 2007;68(9):1384–1391.
356.Sasso DA, et al. Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors. J Clin Psychopharmacol 2006;26(6):685–687.
357.Odlaug BL, Grant JE. N-acetyl cysteine in the treatment of grooming disorders. J Clin Psychopharmacol 2007;27(2):227–229.
358.Monzani B, et al. Prevalence and heritability of skin picking in an adult community sample: a twin study. Am J Med Genet B Neuropsychiatr Genet 2012;159B(5):605–610.
359.Coccaro EF, et al. Intermittent explosive disorder-revised: development, reliability, and validity of research criteria. Compr Psychiatry 1998;39(6):368–376.
360.McCloskey MS, et al. Intermittent explosive disorder-integrated research diagnostic criteria: convergent and discriminant validity. J Psychiatr Res 2006;40(3):231–242.
361.Kessler RC, et al. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006;63(6):669–678.
362.Coccaro EF, et al. Lifetime and 1-month prevalence rates of intermittent explosive disorder in a community sample. J Clin Psychiatry 2004;65(6):820–824.
363.Davidson RJ, Putnam KM, Larson CL. Dysfunction in the neural circuitry of emotion regulation—a possible prelude to violence. Science 2000;289(5479):591–594.
364.Coccaro EF, et al. Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression. Biol Psychiatry 2007;62(2):168–178.
365.Coccaro EF. Intermittent explosive disorder as a disorder of impulse aggression for DSM-5. Am J Psychiatry 2012;169(6):577–588.
366.Goveas JS, Csernansky JG, Coccaro EF. Platelet serotonin content correlates inversely with life history of aggression in personality-disordered subjects. Psychiatry Res2004;126(1):23–32.
367.Frankle WG, et al. Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. Am J Psychiatry 2005;162(5):915–923.
368.Rosell DR, et al. Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients. Biol Psychiatry 2010;67(12):1154–1162.